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Abstract 
Phosphorylation of polybasic stretches in membrane-associated proteins creates an 
electrostatic switch influencing their interactions with membrane lipids. Such modification 
affects their localization, conformational fluctuations and ultimately function. One example 
for this is the epidermal growth factor receptor (EGFR), which is involved in the 
pathogenesis of many cancers.  
EGFR activation is coupled to a conformational change, where the intracellular domain is 
released from an autoinhibitory interaction with the plasma membrane after ligand induced 
calmodulin (CaM) binding. The CaM dependent receptor activation occurs in analogy to 
the ion channel KCa3.1, which is regulated via histidine phosphorylation. Histidine 
(His358) phosphorylation of the KCa3.1 channel by nucleoside diphosphate kinase B 
(NME2) induces binding of the active calcium-CaM complex and further activation, while 
dephosphorylation by phosphohistidine phosphatase 1 (PHPT1) results in an inactive 
conformation.  
For EGFR, a single histidine residue (His648), located in the polybasic CaM binding 
domain (BD), may act as a possible regulatory site. This study demonstrates that the His648 
residue is essential for intact ligand induced EGFR activation. For the first time, PHPT1 is 
identified as a new key player in regulating EGFR activation. Transient PHPT1 
overexpression amplifies Tyr phosphorylation of spontaneously activated EGFR, whereas 
the ligand induced EGFR phosphorylation is reduced. The previously identified oncogenic 
propensities of PHPT1 could be explained by its enhancement of spontaneous EGFR 
activation. In addition, the phosphohistidine kinases NME1 and NME2 show the opposite 
effect in regulating EGFR activation, indicative for a regulation of EGFR activation by the 
phosphohistidine phosphatase/kinase system in vertebrates. Furthermore, the results suggest 
that PHPT1 modulates receptor activation in absence and presence of ligand in two 
independent mechanisms. 
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Zusammenfassung 
Die Phosphorylierung von Membranproteinen, speziell in dessen polybasischen Segmenten, 
kann als elektrostatischer Schalter fungieren. Dieser reguliert die Interaktion mit 
Membranlipiden und folglich die Lokalisierung, Konformationsänderung bis hin zur 
Funktion der Proteine. Ein Beispiel für ein Membranprotein, dessen Konformation durch 
elektrostatische Interaktionen mit der Plasmamembran bestimmt ist, ist der EGF-Rezeptor 
(engl. epidermal growth factor). Dieser ist in der Pathogenese verschiedenster Krebsarten 
involviert. 
Die EGFR Aktivierung geht mit einer Konformationsänderung einher, in der nach 
Ligandenstimulation die intrazelluläre Domäne des Rezeptors das regulatorische Protein 
Calmodulin (CaM) bindet und somit die autoinhibitorische Interaktion zwischen 
Plasmamembran und Rezeptor C-terminus aufgehoben wird. Die CaM abhängige 
Rezeptoraktivierung verläuft in Analogie zu einem weiteren Membranprotein, dem 
Ionenkanal KCa3.1, dessen Aktivität mittels Histidinphosphorylierung reguliert wird. 
Während dieses Regulationsprozesses wird der Ionenkanal von der Nukleosid Diphosphat 
Kinase B (NME2) phosphoryliert (H358), woraufhin der Calcium-CaM Komplex gebunden 
und der aktive Konformationszustand eingeleitet wird. Die Dephosphorylierung durch die 
Phosphohistidin Phosphatase 1 (PHPT1) führt hingegen zur Inaktivierung.  
Ein allein stehendes Histidin (His648), lokalisiert in der CaM Bindedomäne des EGFRs, 
dient demnach womöglich als regulatorische Phosphorylierungsstelle. In dieser Arbeit wird 
gezeigt, dass das Histidin (His648) essenziell für eine intakte ligandenabhängige 
Rezeptoraktivierung ist. Des Weiteren führt die transiente Überexpression der Phosphatase 
PHPT1 zu einer amplifizierten Tyr Phosphorylierung von spontan aktivierten 
Rezeptormolekülen, wohingegen die ligandenabhängige Phosphorylierung reduziert wird. 
Somit wird PHPT1 erstmals als neue Schlüsselkomponente in der Regulierung der EGFR 
Aktivierung identifiziert sowie die möglichen Ursachen ihres onkogenen Potentials, 
basierend auf einer amplifizierten spontanen Aktivierung des EGFRs. Neben der 
Regulation durch PHPT1 wurden die Phosphohistidin Kinasen NME1 und NME2 näher 
untersucht. Diese weisen den entgegengesetzten Effekt zu PHPT1 auf und bekräftigen 
somit, dass die EGFR Aktivierung nicht nur von PHPT1, sondern zudem von dem 
kompletten Phosphohistidin Phosphatase/Kinase System reguliert wird. Darüber hinaus 
Zusammenfassung 
   
 X 
wird gezeigt, dass die spontane sowie die ligandenabhängige Aktivierung durch zwei 
voneinander unabhängigen Mechanismen moduliert wird. 
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   Introduction 
1.1  Charged protein-lipid interaction at the plasma membrane  
In the cascade of gene-RNA-protein networks, much work has been done to investigate 
the role of proteins in regulating gene expression, metabolism and apoptosis. All these 
proteins, acting in a specific network topology, must be regulated spatiotemporally in a 
precise and dynamic manner. Protein regulatory networks have to be flexible enough to 
adapt to changes in the extracellular environment. As part of their localization, proteins 
located at the plasma membrane are the link between the extracellular environment and 
the inside of the cell and they therefore have to be able to recognize extracellular stimuli 
and propagate signals into the cell to translate it into specific cell fates1. 
There are several ways to regulate membrane-bound proteins, one of which is via 
charged protein-lipid interaction. In mammalian cells approximately 70 % of the total 
lipids consist of  glycerophospholipids, while less then 20 % are represented by anionic 
phosphatidylinositol (PtdIns)2. PtdIns are involved in the regulation of signal 
transduction at the plasma membrane by stabilizing the active conformation of 
membrane bound proteins via electrostatic interaction through its negatively charged 
phosphate group. They are also involved in regulating membrane trafficking as well as 
transport functions of membranes3. At structural level, PtdIns consist of an inositol 
molecule linked to the hydrophobic tail via an anionic phosphate group (Figure 1A). 
The acidic phospholipid PtdIns are phosphorylated at the 3`, 4` and 5` positions to form 
PtdIns(4)P, PtdIns(3,4)P2, PtdIns(4,5)P2 and PtdIns(3,4,5)P3, which are enriched in the 
inner leaflet of the plasma membrane to generate a net negative charge. 
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Figure 1: Charged protein-lipid interaction. (A) Structure of the acidic phospholipid PtdIns(3,4,5)P3 as 
an example. (B) Typical charged protein-lipid interaction through electrostatic interactions between the 
acidic phospholipids in the inner leaflet of the plasma membrane and a polybasic sequence of a 
membrane-associated protein. 
For an intact electrostatic protein-lipid interaction the protein requires a positively 
charged lipid-binding domain or a polybasic sequence directly located next to the 
transmembrane domain (Figure 1B). In addition, the interaction becomes stabilized by 
hydrophobic residues, interacting with the acyl chains of the bilayer made up by 
phospholipids4. These interactions are able to locate cytosolic proteins to the plasma 
membrane, thus enabling their biological activity5,6. Additionally, these anionic 
phospholipids facilitate the release of protein domains containing functional sites, which 
recruit effector proteins to enable transmembrane signal transduction7,8. Several 
membrane-bound proteins, like specific ion channels and transporters, require a 
conformational change to get activated. This change of conformation is regulated by 
several components, whereas the electrostatic interaction with PtdIns(4,5)P2 represents 
one of them9,10.  
1.2  Regulation of charged protein-lipid interaction 
The ionic protein-lipid interaction between phosphorylated PtdIns in the plasma 
membrane and polybasic protein sequences are regulated by different factors. One 
important second messenger is the calcium cation Ca2+, which is able to neutralize 
negatively charged phospholipids, regulate PtdIns degradation and activate calmodulin 
A
B
Basic residues
Zwitterionic phospholipids
Acidic phospholipids
O
O
O
P
O
O
O
HO
OPO32-
OPO32-
OPO32-
OH
HO
O
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(CaM), which acts as a competitor to interrupt the protein-lipid interaction11,12,13. The 
role of the Ca2+-binding molecule CaM is to transfer the Ca2+ signal by modulating the 
activity of downstream enzymes. It has no catalytic activity on its own, only consisting 
of a negatively charged surface to bind polybasic proteins interacting with the enriched 
anionic phospholipids in the plasma membrane. The additional negative charges induce 
an electrostatic repulsion causing an interruption of the protein-lipid interaction14,15,4. 
One membrane-associated protein, regulated through this mechanism, is the potassium 
channel KCa3.1. CaM is constitutively bound to its cytosolic C-terminal tail, where 
Ca2+ binding induces the open state of the channel16. The CaM binding domains (CaM-
BD) include a series of basic and hydrophobic amino acid residues going from L344 to 
Q353 (L344AAINAFRQ353) and from K360 to K373 (K360LREQVNSMVDISK373) 
surrounding a single histidine (His) residue His35817. Activation of the ion channel 
KCa3.1 requires PtdIns(3)P and phosphorylation of His358, which is catalysed by 
nucleoside diphosphate kinase-B (NME2), while the dephosphorylation by 
phosphohistidine phosphatase 1 (PHPT1) inhibits the channel by forming the closed 
state18,19,20. The exact mechanism how His phosphorylation and CaM binding regulate 
KCa3.1 activation has so far not been fully elucidated. Not only ion channels are 
regulated by protein-lipid interaction21,22, also G-protein coupled receptors (GPCR)23, 
transporter proteins24 or receptor tyrosine kinases like the epidermal growth factor 
receptor (EGFR)25 reveal those regulation mechanisms. Additionally, EGFR is activated 
in a CaM dependent manner and reveals a single His residue located in the polybasic 
CaM binding domain such as the ion channel KCa3.1. 
1.3  Epidermal Growth Factor Receptor 
1.3.1   Clinical significance 
The membrane-bound protein EGFR is a receptor tyrosine kinase belonging to the ErbB 
family. Due to its role as signal transducer, EGFR activation regulates various cellular 
processes including proliferation, differentiation and survival. The role of aberrant 
EGFR activity and expression level in oncogenesis has been extensively studied and 
shows a broad clinical significance26,27,28. Overexpression or mutations in ErbB family 
members are causing an amplified receptor activation, which leads to more than 30 % of 
breast cancers, 40 % of glioblastomas and 60 % of non-small-cell lung cancers29,30,31. 
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Therefore, it is important to elucidate the exact mechanism of EGFR activation and to 
identify the involved key players in its regulation. 
1.3.2   Structure and activation mechanism of EGFR 
EGFR consists of an extracellular part, separated into domains I-IV, followed by a 
transmembrane (TM) helix and an intracellular part. The intracellular part contains a 
kinase domain and a flexible C-terminal tail, linked to TM helix by a juxtamembrane 
(JM) segment (Figure 2A)32,33.  
 
Figure 2: Architecture of EGFR. (A) Domain architecture of EGFR. (B) Ligand dependent activation of 
receptor forming an asymmetric active dimer conformation, which activates kinase activity and induces 
further auto-phosphorylation. (Figure adapted from Kovacs et al. 201534)  
Ligand binding occurs via the extracellular part causing a conformational change, which 
forms an active asymmetric dimer conformation (Figure 2B). Therefore, the 
A
B
pY845
pY1068
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extracellular domain switches between two states, the compact tethered and the 
extended form promoting dimerization35. The extended state facilitates the formation of 
a helical dimer between two TM a-helices associated through N-terminal GxxxG-like 
motifs36. This conformational change is required to form an antiparallel helical dimer 
between the JM segments of two receptor molecules, which stabilizes the asymmetric 
dimer conformation37. Finally, the asymmetric kinase dimer is formed, in which one 
kinase domain, the activator, switches on the receiver kinase38. The active kinase 
domain induces a trans-phosphorylation of tyrosine (Tyr) residues located in the 
catalytic loop and in the C-terminal tail, which are recognized by effector proteins to 
release downstream signalling cascades34. EGFR gets Tyr phosphorylated at different 
positions. Tyr845, located in the activation loop of the kinase domain, represents a 
phosphorylation site, which has a regulatory autocatalytic function by increasing EGFR 
activity39. Therefore, it regulates several cellular processes such as cell proliferation, 
metabolism as well as cell cycle control. The residue is not only auto-phosphorylated by 
EGFR, but additionally external-phosphorylated by Src kinase40. For receptor signal 
propagation, the effector protein growth factor receptor bound protein 2 (Grb2) has to 
bind phosphorylated Tyr1068 at the C-terminal tail of EGFR, thus resulting in Tyr1068 
acting as a signalling site (Figure 2B)41. 
EGFR does not only form dimers, but also higher-order clusters have been observed 
after receptor activation42. The ligand dependent activation of EGFR is well studied, 
while the activation mechanism in absence of ligand has to be further elucidated. It has 
been shown that the spontaneous activation of the receptor occurs through short-lived 
dimers due to thermal fluctuations in the plasma membrane and only at high expression 
level43,44,45. There is evidence for distinct molecular states, where spontaneous EGFR 
activation takes place mainly in the monomeric state46. 
1.3.3   Regulation of EGFR activity by receptor internalization 
EGFR activity is controlled by intracellular trafficking (endocytosis), which induces 
receptor recycling or degradation. This prevents a hyperactivation of the receptor on the 
plasma membrane, which would turn normal cells into malignant cells. Therefore, the 
majority of ligand bound EGFR is internalized via clathrin-mediated endocytosis 
(CME). The phosphorylation of Tyr1045 recruits c-Cbl, an E3 ligase, which 
ubiquitinates the receptor47. The polyubiquitinated receptor is recruited to clathrin-
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coated pits and induces a unidirectional vesicular trafficking causing lysosomal 
degradation. First, the ligand-receptor complex located in clathrin-coated vesicles 
(CCVs) fuse to early endosomes (EE). These endosomes maturate to late endosomes 
(LE) and multi vesicular bodies (MVB) and fuse with lysosomes for final protein 
degradation48,49. In contrast to the lysosomal degradation of ligand bound EGFR, the 
spontaneous activated EGFR monomer induces a continuous recycling back to the 
plasma membrane through the recycling endosome (RE)46. Compared to the ligand 
bound mechanism, the receptor is not ubiquitinated, which is the signal for sorting into 
late endosomes and lysosomal degradation. In both cases, the signalling is terminated by 
dephosphorylation, catalysed by specific phosphatases in the perinuclear area.    
1.3.4   JM-PM interaction as an autoinhibitory mechanism 
There are several mechanisms regulating EGFR in terms of signalling onset and 
termination in the cell. In addition to the vesicular trafficking, the autoinhibitory 
mechanisms of EGFR create a highly energetic barrier, which has to be overcome to 
activate the receptor. Autoinhibition of EGFR occurs on many levels including the 
closed, tethered state of the extracellular domain50, the disordered N lobe dimerization 
interface of the kinase domain39 and the electrostatic interaction between the 
intracellular part and the plasma membrane51, which stabilize the inactive 
conformational state. The JM segment, involved in the electrostatic interaction between 
receptor and plasma membrane, plays an important regulatory role for EGFR activation. 
Depletion of the JM region prevents the phosphorylation of the C-terminal tail, which 
normally transduces signalling52. In addition, oncogenic EGFR JM mutations (V665M 
and L679F), increasing receptor activation, thus revealing a clinical importance for this 
domain29.  
The JM region is divided into two segments, the N-terminal JM-A and C-terminal JM-B 
part. It contains abundant positively charged residues forming a polybasic sequence 
directly located next to the transmembrane domain. The active conformational state 
reveals an antiparallel helix dimer for JM-A, formed between two L655RRLL659 motifs25, 
whereas one JM-B segment of an acceptor kinase extensively interact with the kinase C-
lobe of a donor kinase (Figure 3A)53,54. In contrast to this, it has been observed that JM-
A is embedded in the plasma membrane when the inactive conformation is formed. 
Therefore, hydrophobic residues of this segment interact with the interior of the plasma 
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membrane bilayer and basic residues with the anionic head groups of PtdIns(4,5)P251,55. 
Not only the JM is involved in interacting with the plasma membrane, also the kinase 
domain contains hydrophobic and basic residues, which promote the embedded 
state38,56. Both conformational states, the inactive and active one, are stabilized by 
electrostatic interactions with the plasma membrane, whereas the inactive embedded 
state is favoured. 
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Figure 3: The JM conformation during EGFR activation. (A) EGFR interaction with the plasma 
membrane in the inactive (OFF) and active (ON) state. Extracellular part is excluded for simplification. 
(B) Sequence of the TM and intracellular part, especially of JM-A segment in detail. (Figure adapted 
from Endres et al. 201456) 
Within the JM of EGFR, there are three clusters of positively charged residues 
(R645RR647, R651KR653 and R656R657) interacting with anionic lipids PtdIns(4,5)P2, which 
are enriched in the cell membrane encompassing the receptor molecules (Figure 3B)57. 
The first positive cluster (R645RR647) is located directly next to the plasma membrane 
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and interacts with PtdIns(4,5)P2 to stabilize the active anti-parallel helical dimer of two 
JM-A segments away from the membrane25. Within the JM there are two single 
threonine (Thr) residues Thr654 and Thr669, located in JM-A directly next to the 
LRRLL-motif and in JM-B. These sites are phosphorylated and act as regulatory 
sites58,59. In both cases phosphorylation lead to an impaired EGF-induced EGFR 
phosphorylation52. Furthermore, there is one single His residue (His648) located in the 
polybasic stretch of the JM-A segment, which has been overlooked by previous studies. 
Additionally, the JM-A segment contains a CaM-binding domain (CaM-BD) 
(R645RRHIVRKRTLRRLLQ660)60. In recent studies it has been demonstrated that CaM 
binds EGFR and facilitates the ligand dependent activation, while the receptor activity 
is inhibited by mutating this region61. EGF stimulation increases the intracellular 
calcium ion concentration generating active Ca2+-CaM complexes, which bind EGFR 
and release the intracellular part from the membrane surface by suppressing the inactive 
embedded state (Figure 4)62,63,64. Therefore, CaM facilitates the ligand activation of 
EGFR.  
 
Figure 4: Suppression of the inactve embedded EGFR state by CaM. Release of the intracellular part 
of EGFR after EGF stimulation by CaM binding. 
While Thr654 phosphorylation inhibits CaM binding and therefore reduces ligand-
induced EGFR activation, Thr669 phosphorylation shows no effect65. The detailed 
regulatory mechanism based on how JM is affecting EGFR activation, has to be further 
elucidated.  
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1.4  Phosphohistidine phosphatases and kinases 
1.4.1   Phosphohistidine as posttranslational modification 
Posttranslational protein modification by phosphorylation is a key mechanism in the 
regulation of signalling cascades from cell surface receptors to the nucleus. A receptor 
molecule gets activated at the plasma membrane and binds other effector proteins in the 
cytoplasm and activates a signalling network. Finally, the signal is transmitted to the 
nucleus, where transcription factors regulate essential cell processes like proliferation or 
apoptosis66. While the O-phosphorylation of serine (Ser), Thr and Tyr residues has been 
extensively studied in signal transduction, N-phosphorylation of His residues remains 
poorly understood in mammalian cells67,68,69. His phosphorylation turns out to be 
challenging to detect due to its instability caused by the unstable phosphoramidate bond, 
which is generated by phosphorylating an imidazole ring (Figure 5). There exist two 
isoforms 1- and 3-phosphohistidine. Due to the highly energetic P-N bond, 
phosphohistidine represents a short-lived posttranslational modification, undergoing 
dephosphorylation even under acidic conditions and at elevated temperature70. 
Therefore, His phosphorylation represents a new overlooked posttranslational 
modification, which might be more essential for signal transduction in mammalian cells 
than what previous studies have shown. 
Introduction 
   
 21 
 
Figure 5: O- and N-phosphorylated amino acids. Stable phosphoester of O-phosphorylated amino acids 
pSer, pThr and pTyr (blue) and labile phosphoramidate of N-phosphorylated His, 1-pHis and 3-pHis 
(red).  
1.4.2   PHPT1 and NDPK 
There are phosphatases catalysing the dephosphorylation of phosphohistidine, like the 
phosphoserine and phosphothreonine phosphatases, PP1, PP2A, PP2C and PGAM571,72. 
Besides the phosphatase LHPP, which is known to dephosphorylate His residues in 
vitro73,74, only one specific phosphohistidine phosphatase (PHPT), PHPT1, has been 
identified in mammalians to date75. PHPT1 shows potential clinical relevance. It is 
involved in the tumour invasion and migration in lung cancer cell lines76,77 and it also 
affects the cell proliferation and differentiation in glioblastoma cells and rapidly 
dividing epithelial human tissue78. Overexpression of PHPT1 induces cell damage in 
human umbilical-vein endothelial cells79, an increased tumour size of clear-cell renal 
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carcinoma and therefore reduces patient survival80. Due to its carcinogenic potential, 
PHPT1 has been identified as an oncogene. 
PHPT1 is a cytosolic enzyme consisting of 125 amino acids. The secondary structure is 
defined by six b-strands surrounded by two a–helices (Figure 6A). The active site is 
formed by a positively charged region including conserved residues, which binds 
phosphohistidine containing substrates (Figure 6B)81. Mutations in this area of two 
specific His residues (His53 and His102) to alanine (Ala) causes an attenuation of 
phosphatase activity82. Therefore, these specific residues play a crucial role for the 
catalytic activity.  
 
 
Figure 6: Crystal structure of PHPT1. (A) Cartoon representation of PHPT1. The residues His53 and 
His102 are highlighted in green. (B) The postivie (blue) and negative (red) electrostatic potential of 
PHPT1 as a solid surface represantion. (PDB ID: 2HW4) 
In contrast to phosphotyrosine phosphatases, there is no catalytic cysteine (Cys) in the 
active site. Additionally, the C-terminus plays an important role for enzyme activity. A 
depletion of the last five residues leads to a loss of function. Moreover, the primary 
structure of the C-terminus contains highly conserved residues, indicating that the C-
terminus is essential for catalytic activity83. PHPT1 shows a complete different structure 
compared to other phosphatases and no common substrate recognition sequence. 
Therefore, the exact mechanism for substrate recognition and catalysis remains to be 
elucidated in the future81.  
If His residues are dephosphorylated, it must exist a kinase catalysing the reverse 
reaction. A small kinase, nucleoside diphosphate kinase (NDPK), has been identified as 
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a His phosphorylating protein. There are two isoforms of NDPK, NME1 and NME2, 
acting as histidine kinases in mammals84,85. To become catalytically competent, the 
kinase has to oligomerize into a hexamer. NDPKs are involved in nucleotide 
metabolism by forming pHis-containing enzyme intermediates, which transfer the 
phosphate from a nucleoside triphosphate to a nucleoside diphosphate86,87. Furthermore, 
it has been shown that auto-phosphorylated NDPK transfers the highly energetic 
phosphoryl group to His containing substrate proteins67. Additionally, the auto-
phosphorylated state increases the affinity to lipids causing a recruitment of cytosolic 
NDPKs to the membrane, where the enzyme phosphorylates several membrane 
proteins88. While PHPT1 acts as an oncogene, the kinases NME1 and NME2 have been 
identified as metastasis suppressor genes89. 
1.4.3   Common targets of PHPT1 and NDPK 
PHPT1 and NDPK represent the phosphatase-kinase system for His phosphorylation in 
mammalian cells (Figure 7A). Several common targets of PHPT1 and NDPK have been 
identified, like adenosine triphosphate citrate lyase (ACL)90, beta-subunit of G-
proteins91 and two ion channels, transient receptor potential-vanilloid-5 (TRPV5) and 
KCa3.120,92 (Figure 7B).  
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Figure 7: Reversible His phosphorylation in vertebrates. (A) General scheme of regulating His 
phosphorylation by the phosphohistidine kinases NME1 and NME2, and the phosphatase PHPT1. (B) 
Specific His phosphorylated targets regulated by NME1/2 and PHPT1. (Figure adapted from Klumpp et 
al. 200967) 
ACL gets His phosphorylated by NME193, while an overexpression of PHPT1 causes a 
dephosphorylation leading to apoptosis of neuronal cells and a reduced cell viability94,95. 
It is reasonable to conclude that PHPT1 might be involved in neurodegenerative 
diseases84. A second target of PHPT1 is the b-subunit of G-proteins. An overexpression 
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of NME2, phosphorylating His266 of G-proteins, amplifies phosphorylation of G-
proteins` b-subunit,  thus increasing the activation of G-proteins96,85. Due to the G-
protein mediated insulin secretion, an overexpression of PHPT1, results in 
dephosphorylation of pHis26691, causes type 2 diabetes in the human insulin-producing 
b-cell line INS 832/1397. In addition to ACL and G-proteins, two specific ion channels 
have been observed to become His phosphorylated by NME2. One of these is the Ca2+-
permeable ion channel TRPV5, which plays a crucial role in Ca2+ homeostasis in the 
kidneys. By phosphorylating His711 located at the C-terminal tail of the channel, 
NME2 induces the active conformational state and Ca2+ flux in the cell. Subsequently, 
the dephosphorylation catalysed by PHPT1 inhibits the receptor activity92. The second 
ion channel is the Ca2+ activated potassium channel KCa3.1, which adopts its active 
conformation followed by His358 phosphorylation in the intracellular C-terminal tail. 
The phosphorylation is catalysed by NME2, whereas PHPT1 dephosphorylates the 
channel and induces the inactive conformation. A channel inhibition causes a decreased 
Ca2+ influx followed by a reduced proliferation in T-cells due to the Ca2+ dependent T 
cell receptor activation. Both ion channels, TRPV5 and KCa3.1, require the binding of 
active Ca2+-CaM complexes for fully activation20. 
It has been shown that PHPT1 and NDPK affect signal transduction cascades like G-
protein and Ca2+ signalling influencing crucial cellular processes, but more signalling 
cascades regulated by His phosphorylation might be identified in the future.  
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   Objective 
An aberrant EGFR activation plays a crucial role in the cancerogenesis of various types 
of cancers, thus showing a broad clinical significance26,27,28. The receptor gets activated 
in presence of ligand by forming an active asymmetric dimer, while the spontaneous 
activation in absence of ligand occurs mainly in the monomeric state, forming only 
short-lived transient dimers for activation. The ligand induced activation has been 
extensively studied, whereas the spontaneous activation has recently gained more 
attention98.  
The complete mechanism of EGFR activity regulation is not yet fully understood, not 
even all regulators are known. Although previous studies have identified certain 
regulators of EGFR activation such as PTPs, phosphohistidine phosphatases have so far 
not been considered. PHPT1, as the first specific phosphohistidine phosphatase 
identified in vertebrates, regulates the downstream signalling of membrane bound 
proteins like the calcium signalling via the ion channel KCa3.1 or GPCR. In analogous 
to KCa3.1, EGFR contains a CaM binding domain in its polybasic JM and in which a 
single His residue (His648) is located. While KCa3.1 requires His phosphorylation in 
this domain for binding the active calcium-CaM complex and further activation, the 
dephosphorylation by PHPT1 transfers the ion channel to an inactive conformational 
state. This raises the question whether PHPT1 regulates EGFR activation in a related 
mechanism. 
To answer this question, we have to investigate the effect of PHPT1 on spontaneous and 
ligand induced EGFR activation as well as the role of the His648 residue and if it serves 
as a substrate site for PHPT1.  
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   Material and Methods 
3.1  Material 
3.1.1   Chemicals 
2`-deoxyadenosine-5`-triphosphate (dATP) InvitrogenTM Life Technologies 
2`-deoxycytidine-5`-triphosphate (dCTP) InvitrogenTM Life Technologies 
2`-deoxyguanosine-5`-triphosphate (dGTP) InvitrogenTM Life Technologies 
2`-deoxythymidine-5`-triphosphate (dTTP) InvitrogenTM Life Technologies 
Ammonium persulfate (APS) SERVA Electrophoresis 
GmbH 
Ampicillin sodium salt SERVA Electrophoresis 
GmbH 
Bromophenol blue Sigma-Aldrich® 
Complete Mini EDTA-free protease inhibitor tablets Roche Applied Science 
Dil staining   ThermoFisher Scientific  
Dimehtyl sulfoxid (DMSO) SERVA Electrophoresis 
GmbH 
Ethanol J.T.Baker 
Ethylendiaminetetraacetic acid (EDTA) Fluka® Analytical 
Glycerol GERBU Biotechnik GmbH 
Hoechst® 33342 ThermoFisher Scientific 
Kanamycin sulfate GERBU Biotechnik GmbH 
Magnesium chloride (MgCl2) Merck KG 
Methanol Sigma-Aldrich® 
N,N,N`,N`-tetramethylethylenediamine (TEMED) Sigma-Aldrich® 
Phenylmethylsulfonyl fluoride (PMSF) Sigma-Aldrich® 
Phosphatase inhibitor cocktail 2 Sigma-Aldrich® 
Phosphatase inhibitor cocktail 3 Sigma-Aldrich® 
Poly-L-lysine Sigma-Aldrich®  
Roti®-Histofix 4% Carl Roth GmbH 
Sodium azide Sigma-Aldrich® 
Sodium chloride (NaCl) Fluka® Analytical 
Sodium dodecyl sulfate (SDS) Carl Roth GmbH 
Tris-base Carl Roth GmbH 
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Tris-HCl J.T.Baker 
Triton X-100 SERVA Electrophoresis 
GmbH 
Tween 20 SERVA Electrophoresis 
GmbH 
UltraPureTM Agarose InvitrogenTM Life Technologies 
3.1.2   Enzymes, proteins and antibodies 
a-Tubulin mouse (#T6074) (WB 1:2500) Sigma Aldrich® 
Accu Prime Pfx DNA Polymerase (#12344024)   Thermo Fisher Scientific  
Alexa Fluor® 647 Donkey anit-Mouse IgG (#A-
31571) 
Thermo Fisher Scientific 
Alexa Fluor® 647 Goat anti-Rabbit IgG (#A-21244) Thermo Fisher Scientific 
Anti-N1-pHis (1-pHis) Ab (#MABS1330) (WB 
1:200) 
Merck Millipore 
Anti-N3-pHis (3-pHis) Ab (#MABS1351) (WB 
1:200) 
Merck Millipore 
Anti-phospho tyrosine mouse Ab pY72 (p172.1) InVivo Biotech Services 
Bovine serum albumin (BSA) (#B9000S) New England Biolabs 
Chameleon® Duo Pre-stained Protein Ladder  
(#928-60000) 
LI-COR® Biosciences 
EGFR goat Ab (#AF231) (WB 1:500, IF 1:200) R&D System® 
EGFR pY1045 rabbit Ab (#2237) (WB 1:500) Cell Signalling 
EGFR pY1068 rabbit Ab (#2234) (WB 1:500, IF 
1:200) 
Cell Signalling 
EGFR pY845 mouse Ab (#558381) (WB 1:500, IF 
1:200) 
BD PharmingenTM 
EGFR total rabbit Ab (#4267) (WB 1:500) Cell Signalling 
Epidermal growth factor human (#E9644) Sigma Aldrich® 
IRDye® 680RD Donkey anti-Mouse IgG (#925-
68072) 
LI-COR® Biosciences 
IRDye® 800CW Donkey anti-Goat IgG (#925-32214) LI-COR® Biosciences 
IRDye® 800CW Donkey anti-Rabbit IgG (#925-
32213) 
LI-COR® Biosciences 
mCherry mouse Ab (#632543) (IP 1:100) Living Colors® 
mCitrine rabbit Ab (#632592) (IP 1:200) Living Colors® 
NME1 Provided by Stephen Fuhs  
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PfuTurbo DNA Polymerase (#600250) Agilent Technologies 
PGAM1 Provided by Stephen Fuhs 
PHPT1 rabbit Ab (#H6790) (WB 1:1000) Sigma Aldrich® 
Protein-G-Sepharose®, Fast Flow (#P3296-5ML) Sigma-Aldrich® 
Restriction endonucleases New England Biolabs Inc. 
T4 DNA Ligase (#750589) Thermo Fisher Scientific 
3.1.3   Oligonucleotides 
All oligonucleotides were purchased from Eurofins in HPLC purified form. All primer 
sequences are found in supplementary material. 
3.1.4   Plasmids 
EGFR-mCitrine (pmCitrine-N1) Provided by Bastiaens lab 
EGFR-mCitrine H648A (pmCitrine-N1) Provided by Bastiaens lab 
FLAG-NM23-H1 Addgene 
mCitrine (pOPIN) Provided by Dortmund Protein Facility 
(DPF)  
mCitrine-PHPT1 (pOPIN) Provided by Dortmund Protein Facility 
(DPF) 
pcDNA3.1 + InvitrogenTM Life Technologies 
pDONR223-NME2 Addgene 
pmCherry-C1   Clonetech Laboratories Inc.  
pmCherry-N1 Clonetech Laboratories Inc. 
3.1.5   Kits and commercial solutions 
Molecular biology 
10x Pfu amplification buffer InvitrogenTM Life Technologies 
10x Accu Prime Pfx Reaction Mix   Thermo Fisher Scientific  
2-log DNA ladder New England Biolabs Inc. 
5x reaction buffer (T4 DNA ligase) Thermo Fisher Scientific  
6x DNA gel loading buffer Novagen 
BigDye® Terminator v1.1 v3.1 5x Sequencing 
buffer 
Thermo Fisher Scientific  
BigDye® Terminator v3.1 cycle sequencing kit Applied Biosystems 
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E. coli XL-10 Gold StrataGen 
Nucleobond® finalizer Macherey-Nagel 
NucleoBond® Xtra Maxi EF kit Macherey-Nagel 
NucleoSeq Macherey-Nagel 
RedSafe nucleic acid staining solution iNtRON Biotechnology 
Roti®-Prep Plasmid MINI kit Carl Roth GmbH 
ZymocleanTM Gel DNA recovery kit Zymo Research 
 
Cell culture 
Dulbecco`s modified eagle`s medium (DMEM) PANTM Biotech GmbH 
Dulbecco`s phosphate buffered salt solution 
(DPBS) 
PANTM Biotech GmbH 
Fetal calf serum (FCS) PANTM Biotech GmbH 
Fugene® 6 transfection reagent Roche Applied Science 
L-Glutamine GIBCO®/InvitrogenTM 
LipofectamineTM 2000 InvitrogenTM 
MCF-7 (Human mammary gland adenocarcinoma) American tissue culture collection 
(ATCC) 
Non-essential amino acids (NEAA) PANTM Biotech GmbH 
Trypsin 0.25 %/EDTA 0.02 % in PBS PANTM Biotech GmbH 
 
Biochemistry 
30 % Acrylamide/Bis-solution Bio-Rad Laboratories, Inc. 
Bradford reagent Sigma Aldrich® 
NewBlotTM PVDF stripping buffer LI-COR® Biosciences 
Odyssey® Blocking Buffer (TBS) LI-COR® Biosciences 
3.1.6   Buffers and solutions 
Molecular biology 
1xTAE buffer   40 mM Tris/Acetate (pH7.5), 20 mM NaOAc, 1 mM EDTA  
LB agar plate 15 g/L agar in LB medium, pour plates, add antibiotic at 
desired concentration 
LB medium   10 g/L Bacto-trypton, 5 g/L bacto-yeast extract, 10 g/L 
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NaCl, pH 7.4 and finally autoclave  
TB medium 12 g/L trypton, 24 g/L yeast extract, 0.4 % glycerine, 2.31 
g/L KH2PO4, 12.54 g/L K2HPO4 and autoclave 
 
Cell culture 
1xPBS buffer   135 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM 
KH2PO4, pH 7.4  
Complete Growth Media 10 % FCS, 1 % L-Gln , 1 % NEAA in DMEM 
Starvation Media 0.5 % FCS, 1 % L-Gln, 1 % NEAA in DMEM 
 
Biochemistry 
10 % APS 100 mg/mL APS in ddH2O (freshly prepared) 
10 % SDS 100 g/L SDS in ddH2O 
1xLysis buffer 
(Immunoprecipitation)  
50 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM 
EGTA, 10 % glycerol (optional: 0.25 % Na deoxycholate or 
1 % IGEPAL)  
1xRIPA lysis buffer   50 mM Tris pH 7.5, 150 mM NaCl, 1 mM EGTA, 1 mM 
EDTA, 0.25 % Na-deoxycholate, 1 % IGEPAL, 2.5 mM Na-
pyrophosphate, 1 mM b-glycerophosphate in ddH2O 
1xRunning buffer   25 mM Tris-Base, 190 mM glycine, 0.1 % SDS 
1xTBS buffer 50 mM Tris (pH 7.4), 150 mM NaCl 
1xTBS-T 50 mM Tris (pH 7.4), 150 mM NaCl, 0.1 % Tween 20 
1xTransfer buffer 25 mM Tris-Base, 190 mM  
2xLaemmli buffer pH8.8 100 mM Tris-Base (pH 8.8), 20% glycerol, 4% SDS, 20 mM 
EDTA, 200 mM DTT, 0.008 % bromophenol blue 
5xLaemmli buffer   60 mM Tris-HCl (pH 6.8), 25 % glycerol, 2 % SDS, 14.4 
mM 2-mercapto-ethanol, 0.1 % bromophenol blue 
TMD buffer 20 mM Tris-HCl pH 8.0, 5 mM MgCl2, 1 mM DTT 
3.1.7   Equipment 
Centrifuges 
Centrifuge 5417R (4°C) Eppendorf 
Centrifuge 5424 (RT) Eppendorf 
Centrifuge 5810R Eppendorf 
Concentrator Plus Eppendorf 
Material and Methods 
   
 32 
SorvallTM RC 6+ Centrifuge ThermoFisher Scientific 
 
Molecular biology 
Mastercycler® Pro Eppendorf 
Mini Electrophorese Unit Carl Roth 
Molecular Imager Gel Doc XR Bio-Rad Laboratories 
NanoDrop ND-1000 Spectrophotometer Thermo Scientific 
Power PacTM 300 Bio-Rad Laboratories  
 
Cell culture 
TC-Plate 6 Well, Standard, F Sarstedt 
NuncTM Lab-TekTM, 8 well, borosilicate 
coverglass 
Thermo Fisher Scientific 
Corning® 96 well plates (CLS3603)   Sigma-Aldrich  
TC flask T75, Standard Sarstedt 
Vi-CellTM XR cell counter   Beckman Coulter  
 
Biochemistry 
96 well microplates, black, F-bottom Greiner Bio One 
DU® 800 UV/Visible Spectrophotometer Beckman Coulter 
Heating Block QBD4  Grant Instruments 
Immobilon-FL PVDF membrane  Merck Millipore 
Microplate Reader SpectraMax M5 Molecular Devices 
Mini Trans-Blot® Cell Bio-Rad 
Mini-Protean® Comb, 15-well, 1.5 mm Bio-Rad 
Mini-Protean® Tetra Cell System Bio-Rad 
Odyssey® CLx imaging system LI-COR 
PowerPacTM HC  Bio-Rad 
Semi-micro cuvette, PS Sarstedt 
Sonicator Needle (MS 73) Bandelin Electronic GmbH 
Test tube rotator 34528 Snijders 
Ultraschall HD 2200 Bandelin Electronic GmbH  
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Whatman filter paper Thermo Fisher Scientific 
 
Microscopes 
Fiber coupling Uni Picoquant GmbH 
Leica TCS SP8 Leica 
Olympus FluoView FV1000 Olympus 
Sepia II controller Picoquant GmbH 
 
3.1.8   Software 
Adobe Illustrator Adobe Systems Inc. 
DNASTAR Lasergene v12 DNASTAR Inc. 
Fiji Schindelin et al. Nat. Meth. 
(2012)99 
FV10-ASW Fluoview Software Olympus 
GraphPad Prism 6 GraphPad Software Inc. 
IgorPro v6.3 WaveMetrics 
Leica Application Suite X Leica Microsystems 
MacPyMOL v1.8.2.2 Schrödinger 
MS Office 2016 Microsoft Corporation 
Python 2.7 Continuum Analytics 
Sepia II software PicoQuant GmbH 
SymPhoTime v5.12 PicoQuant GmbH 
3.2  Methods 
3.2.1   Molecular biology 
3.2.1.1  Transformation of chemically competent cells 
To introduce foreign DNA into a cell, chemically competent E. coli XL-10 Gold cells 
(100 µL) were gently mixed with plasmid DNA (10 ng), Mutagenesis-PCR mix 
(7 µL) or ligation reaction (10 µL). The DNA/Cell mixture was incubated on ice for 
15 min in the case of circular DNA, while linear DNA had to be incubated for 30 min. 
After heating for 90 s at 42 °C, the tubes were transferred to 4 °C for 2 min. LB medium 
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(800 µL) was added to the bacteria and incubated for 1 h at 37 °C and 200 rpm. For the 
transformation of circular DNA 20 µL were plated out on an antibiotic containing agar 
plate. In presence of linear DNA the cells were centrifuged for 1 min at 10.000 rpm and 
resuspended in a residual volume (100 µL). The cells were transferred to LB agar plates 
containing the appropriate antibiotic and incubated at 37 °C for 16 h. 
3.2.1.2  Bacterial cultivation 
The LB medium containing pre-cultures (5 mL) were inoculated with single E. coli XL-
10 Gold colonies in presence of the appropriate amount of antibiotic. These bacterial 
cultures were incubated for 16h at 37 °C and 200 rpm before isolating the plasmid DNA 
via plasmid preparation.  
3.2.1.3  Isolation of plasmid DNA by using Roti®-Prep MINI kit 
The bacterial cultures (5 mL) were harvested at 13.000 rpm for 2 min and the 
supernatant discarded. The cell pellets were treated according to the manufacturers 
standard protocol to obtain purified plasmid DNA in elution buffer (30 µL). 
3.2.1.4  Endotoxin-Free plasmid DNA purification using NucleoBond® 
Xtra Maxi EF kit 
LB-medium cultures (100 mL) containing the appropriate antibiotic were inoculated 
with single E. coli XL-10 Gold colonies and incubated for 16 h at 37 °C and 200 rpm. 
To prove the cell growth, the optical density was determined at 600 nm (OD600 = 1.5-
2.0). The Cells were harvested for 15 min at 4 °C and 4.000 rpm. After discarding the 
supernatant, the obtained pellets were treated as described in the user manual of the 
manufacturers and finally loaded to NucleoBond® finalizer to elute endotoxin free 
plasmid DNA once with 200 µL TE-EF and during a second elution step with 100 µL.  
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3.2.1.5  Amplification of DNA fragments via Polymerase Chain 
Reaction (PCR) 
The polymerase chain reaction (PCR) was used to amplify a specific DNA sequence. 
Therefore, primers (forward and reverse) were designed complementary to the template 
DNA. The melting temperature Tm was calculated: 𝑇" = 	   2 ∙ 𝑛𝐴 + 𝑛𝑇 + 4 ∙ 𝑛𝐺 + 𝑛𝐶 °𝐶 
The PCR reaction was catalysed by Accu Prime Pfx DNA polymerase under the 
following conditions. 
Table 1: PCR reaction mixture using AccuPrime Pfx DNA polymerase 
 
 
 
 
 
 
 
 
Table 2: Temperature PCR protocol for insert amplification 
Temperature Time Repeats 
95 °C 2 min  
95 °C 15 s  
Tm - 5 °C 30 s 30x 
68 °C 1 min/kbp  
68 °C 10 min  
8 °C ∞  
 
Component Amount 
DNA template 200 ng 
Forward Primer (100 µM) 0.5 µL 
Reverse Primer (100 µM) 0.5 µL 
10xAccu Prime Pfx Reaction Mix 5.0 µL 
Accu Prime Pfx DNA Polymerase (2.5 U/ µL) 0.4 µL 
H2O add to 50 µL 
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3.2.1.6  Site-directed mutagenesis via Quick Change Polymerase Chain 
Reaction (QC-PCR) 
The Quick Change mutagenesis was performed to introduce site-directed mutagenesis in 
a plasmid, by substitution, insertion or deletion of single nucleotides. Therefore, 
complementary primers were designed containing 15bp before and after the desired 
mutation with a Tm of approx. 72 °C. The designed primers are listed in the 
supplementary material. The PCR was catalysed by PfuTurbo DNA Polymerase using 
the conditions represented in Table 3. 
Table 3: Site-directed mutagenesis PCR reaction mixture using PfuTurbo DNA polymerase 
Component Amount 
DNA template 100 ng 
dNTPs (10 mM) 0.5 µL 
DMSO (100%) 2.5 µL 
Primer (10 µM) 1.0 µL 
10xPfu buffer 2.5 µL 
PfuTurbo DNA Poymerase (2.5 U/µL) 1 µL 
H2O add to 25 µL 
 
Table 4: Site-directed mutagenesis PCR protocol 
Temperature   Time   Repeats  
95 °C   1 min     
94 °C   1 min     
55 °C   1 min   29x  
65 °C   2 min/kbp     
65 °C   5 min     
4 °C   ∞     
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The parental methylated DNA was digested with the restriction enzyme DpnI (10 U/µL, 
1 µL) at 37 °C for 1 h. The digested DNA (7 µL of digested solution) was transformed 
into chemically competent E. coli XL-10 Gold cells (100 µL) via heat shock.  
3.2.1.7  DNA sequencing 
The nucleotide sequence of template DNA was determined by Sanger sequencing 
method, which uses fluorescently labelled 2`,3`-dideoxy-nucleotides (ddNTPs) as chain 
terminators. The sequencing PCR reaction was performed using BigDye Terminator v 
3.1 Cycle sequencing kit according to Table 5. The PCR reaction was purified by a 
NucleoSeq column and evaporated at 60 °C in a vacuum centrifuge. Capillary gel 
electrophoresis was used in our in-house facility Zentrale Einrichtung Biotechnologie to 
quantify the PCR reaction. 
Table 5: BigDye Terminator PCR reaction 
Component Amount 
DNA template 500 ng 
BigDye Terminator mix 2 µL 
5xSequencing buffer 4 µL 
Primer (10 µM) 1 µL 
ddH2O add to 20 µL  
 
Table 6: Big Dye Terminator PCR protocol 
Temperature   Time   Repeats  
95 °C   5 min     
95 °C   30 sec     
50 °C   10 sec   26x  
60 °C   4 min     
4 °C   ∞     
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3.2.1.8  Agarose gel electrophoresis of DNA 
For DNA separation by size, agarose gel electrophoresis was performed. Agarose gels 
(0.9 % (w/v)) were prepared by dissolving low-melting point UltraPure agarose (4.5 g) 
in 1xTAE buffer (500 mL) by heating in a microwave for complete dissolution. After 
adding RedSafe nucleic acid staining solution (5 µL/100 mL), the agarose was poured 
into a gel tray and stayed at RT for solidification. The solid gel was placed into 
electrophoresis chamber and covered with 1xTAE buffer. The DNA samples were 
mixed with DNA loading buffer (6x), loaded into the wells next to the 2-log DNA 
ladder (1 µg) and separated at a constant voltage of 120 V for 30 to 60 min depending 
on the gel size. The DNA bound RedSafe has two excitation states (309 and 419 nm), 
which are used to visualize the DNA at the visible emission state (537 nm). To further 
proceed, the desired DNA fragment was excised from the agarose gel and purified using 
the Zymoclean Gel DNA Recovery Kit according to the manufacturers standard 
protocol. Finally, pure DNA was eluted with DNA elution buffer (6 µL). 
3.2.1.9  Restriction digest and ligation of DNA fragments 
Double strained DNA (2 µg) was digested with restriction enzymes (5 U/µL, 1 µL) in 
an appropriate reaction buffer (10x) and a final volume of 40 µL. The reaction was 
performed at 37 °C for 3 h and purified using agarose gel electrophoresis followed by 
the Zymoclean Gel DNA Recovery Kit according to the manufacturers protocol. After 
digestion and purification of the recipient plasmid and insert, both components were 
ligated using a three-fold molar excess of insert DNA. The required insert amount was 
calculated: 
𝑖𝑛𝑠𝑒𝑟𝑡	   𝑛𝑔 = 𝑣𝑒𝑐𝑡𝑜𝑟	   𝑛𝑔 ∙ 𝑖𝑛𝑠𝑒𝑟𝑡	   𝑏𝑝𝑣𝑒𝑐𝑡𝑜𝑟	   𝑏𝑝 	   ∙ 3 
The ligation reaction was catalysed by T4 DNA ligase (1 U/µL, 0.5 µL) in presence of 
5xreaction buffer in a final volume of 20 µL and incubated at 37 °C for 3 h. The crude 
ligation reaction (10 µL) was used for transformation into chemically competent 
bacterial cells (100 µL) via heat shock. 
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3.2.2   Mammalian cell culture 
3.2.2.1  Cultivation of mammalian cells 
The passaging of adherent mammalian cells was exercised in a laminar flow hood under 
sterile conditions. The cells were grown in T75 flasks at 37 °C and 5% CO2 in presence 
of complete growth media consisting of 10% fetal calf serum (FCS), 1% non-essential 
amino acids (NEAA) and 1% L-glutamine (Gln) in Dulbecco`s modified eagle`s 
medium (DMEM). For passaging cells with a confluency of 80-90% the media was 
removed from the culture flask and adherent cells were washed once with phosphate-
buffered saline (PBS) buffer (2 mL per 10 cm2 surface area). PBS supplemented with 
trypsin (0.25%) and EDTA (0.02%) were used to dissociate cells from the cell culture 
vessel (0.2 mL per 10 cm2 surface area), where the incubation time depends on the cell 
line. Complete growth media was transferred to the flask (0.8 mL per 10 cm2 surface 
area) and pipetted up and down. The single cell suspension was used to determine the 
total number of viable cells with the Vi-CellTM XR cell counter from Beckman Coulter. 
The desired cell number was seeded into cell culture vessels and incubated at 37 °C and 
5% CO2. 
3.2.2.2  Transfection with plasmid DNA 
For ectopically protein expression, cells were transiently transfected with plasmid DNA 
showing 70-90% confluency on the day of transfection. The DNA-lipid complexes were 
prepared by diluting LipofectamineTM 2000 DNA transfection reagent (4 µL) and 
plasmid DNA (1.6 µg) separately in serum free medium (100 µL). After incubation for 
5 min at room temperature, the diluted DNA was combined with the diluted transfection 
reagent and again incubated for 20 min. The DNA-lipid complexes were added to the 
well (200 µL per 10 cm2 surface area), containing cells and medium, and were 
incubated for 18 h at 37 °C and 5% CO2. The medium was changed after 6 h to fresh 
complete growth media. While LipofectamineTM 2000 was used to transfect cells for 
further lysate preparation and immunoblotting experiments, cells were transfected with 
Fugene® 6, showing lower cell toxicity effect, but less efficiency, to prepare samples for 
fluorescence microscopy. Therefore, Fugene® 6 transfection reagent (1.5 µL) was 
diluted in serum free medium (25 µL), mixed and incubated for 5 min at RT before 
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adding plasmid DNA (0.5 µg). After a second incubation step for 10 min at RT, the 
Fugene® 6/DNA mixture was transferred to the cells (25 µL per 0.8 cm2), showing 50-
80% confluency, and incubated for 18 h at 37 °C and 5% CO2, while the media was 
changed after 6 h. The transfection efficiency was proved with a wide field fluorescence 
microscope. 
3.2.3   Biochemistry 
3.2.3.1  Cell lysate preparation 
Transiently transfected cells were starved in presence of starvation medium containing 
0.5% FCS, 1% NEAA and 1% L-Gln in DMEM for 4 h at 37 °C and 5% CO2. The 
stimulation took place in presence of epidermal growth factor at various concentrations 
and for different time points. Whole cell lysates for immunoblots were prepared by 
placing the cell culture dishes on ice and washing with ice-cold 1xPBS before adding 
1xRIPA buffer (100 µL per 10 cm2 surface area). After incubation for 15 min, the 
adherent cells were scraped off the dish with a plastic cell-scraper and the cell 
suspension was transferred to pre-cooled Eppendorf tubes to sonicate the samples for 
12 sec, 3 cycles, 30%. The obtained cell lysates were centrifuged at 13.000 rpm and 
4 °C for 15 min and the supernatant transferred to fresh pre-cooled Eppendorf tubes. 
The whole cell lysates were stored at -80 °C after freezing in liquid nitrogen.  
3.2.3.2  Bradford assay 
The protein concentration of the obtained cell lysates was determined by Bradford 
Assay based on a protein-dye complex, which is formed between Coomassie Brilliant 
Blue G-250 and the basic amino acid residues of a protein under acidic conditions, 
which induces an absorbance shift. Serial dilution of bovine serum albumin (BSA) was 
prepared for a standard curve. Water (500 µL) was pipetted into a plastic cuvette and 
lysate (1 µL) or water (1 µL) or BSA (16, 8, 4, 2 and 1 µg/mL) was added. To form the 
protein-dye complex, Bradford reagent (500 µL) was added, mixed and incubated at RT 
for 5 min before measuring the OD at 595 nm with a spectrophotometer. Protein 
concentrations of the cell lysates were calculated based on the BSA standard curve. 
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3.2.3.3  Immunoprecipitation 
Specific proteins were isolated from cell lysates by immunoprecipitation. Therefore, 
Protein-G-Sepharose® beads (500 µL), stored in 20% EtOH, were purified by washing 
with ice-cold 1xPBS (1 mL) and centrifugation at 850 rcf for 2 min at 4 °C. The 
washing step was performed four times until the supernatant was removed with a 
syringe to get rid of all liquid. 1xPBS (500 µL) was added to the beads to obtain a 50% 
Protein-G-Sepharose bead solution. The purified beads (20 µL) were incubated with cell 
lysate (0.5 mg) in a final volume of 500 µL at 4 °C for 2 h on a tube rotator to reduce 
unspecific binding. The unspecific bound fraction was pelleted at 850 rcf for 2 min at 
4 °C and the supernatant used to incubate with the pull-down antibody (5 µL, 1:100) at 
4 °C for 16 h. Freshly purified beads (30 µL) were transferred to the lysate and 
incubated at 4 °C for 2 h. The lysate-bead mixture was diluted with lysis buffer 
(500 µL), centrifuged at 850 rcf for 2 min at 4 °C and washed five times with 1xPBS. 
After the final washing step, buffer was removed with a syringe and protein were eluted 
from the beads in presence of 5x Laemmli buffer (5 µL) and lysis buffer (20 µL) at 
95 °C for 5 min.  
3.2.3.4  In vitro auto-phosphorylation of NME1 and PGAM1 
The purified enzymes, NME1 and PGAM1, were diluted in TMD buffer (10 ng/µL) and 
incubated with substrate. NME1 was auto-phosphorylated in presence of ATP (1 mM) 
for 10 min at RT, while PGAM was incubated with 2,3-DPG (1 mM) for 10 min at 
30 °C. The reaction was terminated by adding 2xLaemmli buffer pH 8.8 and control 
samples were heated at 95 °C for 10 min. 
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3.2.3.5  Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
Denaturing sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
was performed using the Bio-Rad system. Therefore, gels consisting of a stacking and 
separating gel were prepared according to the protocol in Table 7 and  
Table 8. 
Table 7: Protocol for one stacking gel (1.5 mm). 
Component Volume [mL] 
ddH2O 1.72 
Acrylamide/Bis (30%) 0.5 
0.5 M Tris pH 6.8 0.76 
10% SDS 0.03 
10% APS 0.03 
TEMED 0.003 
 
Table 8: Protocol for one separating gel (1.5 mm). 
Component Volume [mL] 
 10% 12% 15% 
ddH2O 4.0 3.3 2.3 
Acrylamide/Bis (30%) 3.3 4.0 5.0 
1.5 M Tris pH 8.8 2.5 2.5 2.5 
10% SDS 0.1 0.1 0.1 
10% APS 0.1 0.1 0.1 
TEMED 0.004 0.004 0.004 
 
To define the pocket size a 15-well comb 1.5 mm was used. The formed pockets can be 
loaded with a sample volume up to 30 µL. The inner and outer buffer chambers of the 
electrophoresis cell were filled with 1xrunning buffer. For sample preparation, equal 
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amounts of protein (30 µg) were heated after adding 5xLaemmli buffer for 5 min at 
95 °C, mixed and centrifuged for 1 min at 13.000 rpm. The samples and Chameleon duo 
pre-stained protein ladder (4 µL) were loaded on the gel. The electrophoresis was 
performed at 80 V for 10 min before increasing the voltage to 110 V for 90 min. 
In order to run a SDS gel for further phosphohistidine detection, a modified stacking gel 
with a pH of 8.8 had to be prepared. The purified enzyme samples (250 ng) were diluted 
with 2xLaemmli buffer pH8.8. The heating step was omitted due to the temperature 
lability and the electrophoresis was performed at 100 V and 4 °C for 3 h. 
3.2.3.6  Western blot 
Proteins were eluted from gels and transferred to membranes using the electrophoretic 
transfer with a tank blotting Bio-Rad system. Therefore, the gel holder cassette, foam 
pads and Whatman filter paper were put into a tray filled with precooled 1xtransfer 
buffer. Polyvinylidene fluoride (PVDF) membrane was first activated in MeOH for 
2 min and then equilibrated as well as the pre-cut SDS gel in 1xtransfer buffer for 
5 min. The equilibrated gel was transferred to the filter paper, positioned on a foam pad, 
followed by the PVDF membrane and a second filter paper treated with a roller to avoid 
trapped air bubbles. The gel holder cassette, including the described membrane gel set 
up, was placed into the transfer tank, while the gel was facing the cathode. After adding 
an ice block and a magnetic stirrer, the tank was filled with precooled 1xtransfer buffer 
and the electrophoretic transfer was performed at 100 V for 90 min under continuous 
stirring. The protein containing membrane was blocked at RT for 1 h with Odyssey® 
Blocking Buffer (TBS) before primary antibody diluted in 1xTBS-T (dilution ratio 
varied between antibodies) was incubated over night at 4 °C under continuous shaking. 
Washing of the membrane was performed in presence of 1xTBS-T three times for 
10 min. Antibodies labelled with different infrared dye fluorophores (1.5 µL) from LI-
COR diluted in 1xTBS (10 mL) were used as secondary antibodies for multi-color 
detection. Therefore, the secondary antibodies were incubated at RT for 1 h in the dark. 
The stained membrane was rinsed three times with 1xTBS-T for 5 min and scanned 
with an Odyssey® CLx imaging system from LI-COR. For all western blots Tubulin 
served as an internal reference and loading control. For further re-probing, the 
membrane was stripped with NewBlotTM PVDF stripping buffer (1 mL) diluted with 
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ddH2O (4 mL) for 20 min at RT. After rinsing with 1xPBS three times for 5 min, the 
membrane was scanned to ensure complete antibody removal and re-probed again with 
primary and secondary antibody described before. 
3.2.3.7  Internalization assay 
The internalization of EGF receptor was observed with an On-Cell Western Assay by 
monitoring the loss of receptor molecules on the cell surface. Therefore, Corning® 96 
well plates in black and with clear flat bottom wells were coated with poly-L-lysine 
(5mg in 50 mL 1xPBS). The coating solution was incubated (50 µL per 0.3 cm2 surface 
area) for 5 min at RT, removed and the wells were washed with sterile 1xPBS for 5 min 
at RT.  The plates were allowed to dry over night or at least 2 h before seeding MCF7 
cells (1x104 per 0.3 cm2 surface area). The cells were transiently transfected after 24 h 
with EGFR_mCitrine (40 ng) and mCitrine empty vector or mCitrine_PHPT1 (20 ng) in 
presence of Fugene 6 (50 µL per 0.3 cm2 surface area) described in chapter 3.2.2.2. 
After 6 h the medium was removed and replaced by fresh complete growth medium 
(200 µL per 0.3 cm2 surface area). The cells were starved (90 µL per 0.3 cm2 surface 
area) for 5 to 6 h with starvation medium containing 0.5% FCS after 16 to 18h and then 
stimulated with EGF (10 µL of 1000 ng/mL) at 37 °C for different time points. The old 
media was removed and Roti®-Histofix 4% (50 µL per 0.3 cm2 surface area) was slowly 
added for 5 min at RT for cell fixation. The cells were washed three times with 1xTBS 
for 5 min (100 µL per 0.3 cm2 surface area) and blocked with Odyssey® Blocking 
Buffer (TBS) (50 µL per 0.3 cm2 surface area) for 30 min at RT without 
permeabilization. As primary antibody human EGFR/ErbB1 antibody (AF231) (1:200), 
a polyclonal goat IgG binding the extracellular protein domain of EGFR, was diluted in 
blocking buffer (50 µL per 0.3 cm2 surface area) and incubated over night at 4 °C. Cells 
were washed three times with 1xTBS for 5 min before adding IRDye® 800 donkey anti-
goat IgG (1:500) diluted with blocking buffer (50 µL per 0.3 cm2 surface area) for 
30 min at RT. Three final washing steps were performed in 1xTBS for 5 min and the 
plate was scanned with the Odyssey® CLx imaging system. The obtained signal was 
normalized to the cell number using Dil staining solution, a lipophilic membrane dye. 
Therefore, Dil staining solution (1:1000) was diluted with 1xPBS (50 µL per 0.3 cm2 
surface area) and transferred to the cells for 10 min at RT. The staining solution was 
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removed and the fixed cells were washed three times with 1xTBS for 5 min. The dye 
was excited at 549 nm and followed by detecting the emission maxima at 565 nm with 
the microplate reader SpectraMax M5.  
3.2.3.8  Immunofluorescence 
MCF7 cells were seeded (2.5x104 cells per 0.8 cm2 surface area) into 8-well labteks and 
transiently transfected with EGFR_mCitrine (400 ng) and pcDNA3.1 or 
mCherry_PHPT1 (100 ng) in presence of Fugene 6 (25 µL per 0.8 cm2 surface area) 
described in chapter 3.2.2.2. After 6 h the medium was removed and replaced by fresh 
complete growth medium (300 µL per 0.8 cm2 surface area). The cells were starved 
(225 µL per 0.8 cm2 surface area) for 5 to 6 h with starvation medium containing 0.5% 
FCS after 16 to 18 h and then stimulated with different EGF concentrations (25 µL per 
0.8 cm2 surface area) for 5 min at 37 °C. The old media was discarded and the cells 
were rinsed once with 1xPBS at RT before adding Roti®-Histofix 4% (250 µL per 
0.8 cm2 surface area) for 5 min at RT to fix the cells. The fixed samples were washed 
three times with 1xTBS (250 µL per 0.8 cm2 surface area) for 5 min at RT and 
permeabilized in presence of 0.1 % Triton-X100 in 1xTBS (250 µL per 0.8 cm2 surface 
area) for 5 min at RT. After three additional washing steps with 1xTBS for 5 min, 
unspecific binding was blocked with Odyssey® Blocking Buffer (TBS) (200 µL per 
0.8 cm2 surface area) at RT for 1 h. For EGFR phospho staining a mouse anti-EGF 
receptor pY845 and rabbit anti-EGF receptor pY1068 antibody were diluted (1:200) in 
blocking buffer (200 µL per 0.8 cm2 surface area) and incubated over night at 4 °C. The 
samples were washed with 1xTBS three times for 5 min and incubated with secondary 
antibody Alexa Fluor® 647 donkey anti-mouse IgG or chicken anit-rabbit IgG diluted 
(1:200) in blocking buffer (200 µL per 0.8 cm2 surface area) at RT for 1 h. 1xPBS was 
used three times to wash the cells for 5 min and Hoechst® 33342 dye to stain the 
nucleus. Therefore, the nucleic acid stain Hoechst® 33342 (10 mg/mL, 1:10.000) was 
diluted with 1xPBS (200 µL per 0.8 cm2 surface area). The buffer was removed and the 
cells were covered with the staining solution for 5 min at RT. To get rid of the dye, the 
samples were washed three times with 1xPBS for 5 min and stored in 0.1% azide in 
1xPBS at 4 °C for longer storage or only in 1xPBS at 4 °C for short storage.  
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3.2.4   Fluorescence microscopy 
3.2.4.1  Laser Scanning Confocal Microscopy (LSCM) 
Laser scanning confocal microscopy was performed to image fixed cells for 
immunofluorescence experiments using the Leica TCS SP8 and the Olympus FluoView 
FV1000 for additional FLIM measurements. The settings in Table 9 were used for the 
Leica TCS SP8 microscope.  
Table 9: Excitation wavelength, source and emission filters used for Leica TCS SP8. 
Fluorophore/Dye Laser Excitation Emission band 
width 
Detector 
Hoechst® 33342 405 nm Diode 405 nm (15 %) 415-500 nm PMT1 
mCitrine WLL 514 nm (10 %) 524-550 nm HyD2 SMD1 
mCherry WLL  561 nm (5 %) 571-620 nm HyD4 SMD2 
Alexa647 WLL  633 nm (20 %) 643-768 nm HyD 5 
 
The samples were imaged sequentially as a frame average of two images and with a HC 
PL APO CS2 x 63/1.4 NA oil objective using the counting mode in a temperature 
controlled incubation chamber at 37 °C. For the Olympus Fluo View FV1000 confocal 
images of fixed cells were obtained using the following settings in Table 10. 
Table 10: Excitation wavelength, source and emission filters used for Olympus Fluo View FV1000. 
Fluorophore Laser Excitation Emission band with   Beam splitter 
mCitrine argon 488 nm (10 %) 498-551 nm SDM560 
mCherry DPSS 561 nm (5 %)  575-675 nm  
 
The UPLSAPO 60x/1.35 NA oil objective and excitation dichroic mirror 
DM405/488/561/633 were used to focus the excited light. The imaging was performed 
sequentially as a frame average of 2 images in an incubation chamber at 37 °C. The 
background of the obtained images was subtracted and single cell masks were generated 
to measure the mean fluorescence intensity for each channel with ImageJ 
(http://imagej.nih.gov/ij/). The relative phosphorylation level (pY/EGFR) were 
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calculated for each cell. To quantify the relative phosphorylation level of EGFR in 
space, the individual cells were split into ten segments with equal radius from the 
plasma membrane to the nucleus and the mean fluorescence intensity was measured for 
each segment. 
3.2.4.2  Fluorescence Lifetime Imaging Microscopy (FLIM) 
For FLIM measurements the Olympus Fluo View FV1000 laser scanning confocal 
microscope was set up with an external PicoQuant`s compact FLIM and FCS upgrade 
kit. The measurements were performed with a UPLSAPO 60x/1.35 NA oil objective. 
PicoHarp 300, a digitally modulatable driver, controlled the pulsed laser via Sepia II 
Software. The pulsed 40MHz laser was detected with an avalanche photodiode (APD) 
during an image integration time of 3 min and the signal was transferred to the 
PicoHarp 300 data acquisition unit. The 470 nm pulsed laser line (37 %) and the 
dichroic mirror DM470/532 were used to bring the fluorophore mCitrine in its excited 
state and the fluorescence was detected by an APD using a 525/15 bandpass filter. The 
acquired images were analysed according to the global analysis of time correlated 
FRET-FLIM data100. 
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   Results 
4.1  Effect of PHPT1 on EGFR activation 
An increased EGFR activity is linked to various types of cancer101,102. Due to the high 
clinical significance, identification of EGFR regulating factors is of utmost importance. 
Currently, several PTPs have been identified. Here, the effect of PHPT1 on EGFR 
activation was investigated. Accordingly, the relative phosphorylation level of the 
receptor, indicative for receptor activation, was detected in presence of PHPT1 for the 
spontaneous and ligand induced activation. As a readout, specific phosphorylation sites 
of EGFR with distinct functionalities were detected, pTyr1068 as signalling and 
pTyr845 as regulatory autocatalysis site. 
4.1.1   Spontaneous activation of EGFR in presence of PHPT1 
In absence of ligand, EGFR activation and further downstream phosphorylation occur at 
high receptor expression level due to thermal fluctuations. To investigate the effect of 
PHPT1 on the ligand independent EGFR activation mechanism, spontaneous activation 
was artificially induced by transfecting low and high EGFR cDNA amounts in presence 
of PHPT1 into MCF7 cells, containing low endogenous EGFR. The general Tyr 
phosphorylation (pY72) and the specific phospho sites pTyr1068 and pTyr845 were 
detected in absence and presence of PHPT1 in immunoblotting experiments (Figure 8). 
Since the location of the fluorescence protein, recombinantly expressed with PHPT1, 
showed no difference and with the knowledge that PHPT1 requires its flexible C-
terminus for catalytic activity, the experiments were performed with an N-terminal 
tagged phosphatase. The results revealed an amplification of EGFR phosphorylation by 
PHPT1. 
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Figure 8: PHPT1 amplifies spontaneous EGFR activation. Immunoblotting experiments of 
unstimulated MCF7 cells transfected with increasing amounts of wt_EGFR_mCitrine cDNA (0.6 and 
1.2 µg) and wt_PHPT1_mCitrine (0.3 µg). The cells were probed for general receptor phosphorylation 
(pY72) (A),  the autocatalysis (Tyr845) (B) and the signalling (Tyr1068) phospho site (C). The relative 
phosphorylation level (pY over EGFR) was peak normalized and plotted for the indicated conditions. All 
blots are n=2-3 (mean ± SEM). 
Densitometric analysis of the western blots displayed that PHPT1 increased the general 
Tyr phosphorylation level (pY72) of EGFR at high receptor expression level. The 
autocatalytic (pY845) as well as the signalling (pY1068) phospho-sites were involved in 
this effect, showing an amplified relative phosphorylation level in presence of PHPT1. 
To verifiy the cell population-based immunoblotting experiments, single cell 
immunofluorescence experiments were performed (Figure 9). Here, EGFR was 
ectopically co-expressed with PHPT1 in MCF7 cells. The receptor phosphorylation was 
detected in absence and presence of PHPT1. Since the receptor activation occurs at the 
plasma membrane, the cells were spatially segmented into 10 segments and the plasma 
membrane segment (segment 1) were considered for the analysis of the relative 
phosphorylation level. In addition, the phosphorlyation level was plotted for each 
segment to trace the signal regulation of cells in space going from the plasma membrane 
to the nucleus. 
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Figure 9: Enhanced spontaneous EGFR activation by PHPT1. Unstimulated MCF7 cells transfected 
with wt_EGFR_mCitrine (0.4 µg) and wt_PHPT1_mCherry (0.1 µg). Representative 
immunofluorescence images for the signalling phosphorylation site Tyr1068 (A) and autocatalysis site 
Tyr845 (B) (upper, left panels) and the segmentation exemplaric for one cell (upper, right panels). The 
cells were segmented into 10 spatial segments from the plasma membrane (PM) to the nuclear membrane 
(NM). The averaged relative phosphorylation level (pY over EGFR) was plotted for the different 
segments (lower, left panel) (Tyr1068: wt ctrl n=39, wt+P n=27; Tyr845: wt ctrl n=36, wt+P n=53) 
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(mean ± SEM). The relative phosphorylation level of EGFR located at the plasma membrane for single 
cells (lower, right panel) (mean ± STDEV). 
Consistent with the immunoblot experiments, PHPT1 amplified the relative 
phosphorylation of the signalling site pTyr1068 as quantified by immunofluorescence. 
However, the phosphorylation of the autocatalysis site pTyr845 was significantly 
increased in the perinuclear area, unlike the plasma membrane segment. 
4.1.2   Ligand induced EGFR activation in presence of PHPT1 
In addition to the spontaneous activation, the receptor tyrosine kinase activation 
proceeds also in presence of ligand. The effect of PHPT1 on the ligand dependent 
receptor activation was monitored via immunoblot experiments (Figure 10). Here, 
EGFR was ectopically co-expressed in absence and presence of PHPT1 and the cells 
stimulated with increasing doses of EGF for 5 min. As observed in the western blots, 
PHPT1 reduced the phosphorylation level of EGFR and shifted the sigmoid dose 
response curves to the right, while the phosphorylation of the autocatalysis site pTyr845 
showed only a slight shift (Figure 10A). In contrast to this, EGFR required a markedly 
increased amount of ligand to get phosphorylated at Tyr1068 residue and to induce 
further signalling (Figure 10B). 
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Figure 10: Regulation of ligand dependent EGFR activation by PHPT1. EGFR phosphorylation of 
signalling site Tyr1068 (A) and autocatalysis site Tyr845 (B) in a dose dependent manner. MCF7 cells 
were stimulated with different doses of EGF and total lysates were blotted (upper panels). Normalized 
phosphorylation level (pY over Tubulin) was plotted for the indicated logarithmic concentration (lower 
panel). All blots are n=3 (mean ± SEM). 
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Considering the results of the western blots, immunofluorescence experiments were 
performed to validate the inhibitory effect of PHPT1 on EGFR phosphorylation after 
ligand-induced activation (Figure 11). For this, EGFR was co-transfected with PHPT1 
in MCF7 cells and stimulated with saturating EGF dose (c=100 ng/mL) for 5 min. 
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Figure 11: PHPT1 modulates ligand-dependent EGFR activation. EGFR phosphorylation of the 
signalling Tyr1068 (A) and the autocatalysis Tyr845 site (B). Transiently transfected and fixed MCF7 
cells were stimulated with EGF (100 ng/mL, t=5min). Representative fluorescence images for the 
indicated conditions (upper panels). Relative phosphorylation level (pY over EGFR) of EGFR was binned 
for 10 spatial segments from the plasma membrane (PM) to the nuclear membrane (NM) for individual 
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cells and plotted against the segments (lower, left panel) (Tyr1068: wt ctrl n=44, wt+P n=29; Tyr845: wt 
ctrl n=30, wt+P n=35) (mean ± SEM). Relative phosphorylation level of receptor, located at the PM, of 
single cells was plotted for the indicated conditions (lower, right panel) (mean ± STDEV). 
The findings showed that PHPT1 also affected the ligand-induced EGFR 
phosphorylation (c=100 ng/mL) in immunofluorescence experiments. The signalling 
phospho-site Tyr1068 displayed a reduced phosphorylation at the plasma membrane 
consistent with the previous results, whereas phosphorylation of the regulatory 
autocatalysis residue Tyr845 was slightly increased globally in the cell, contrary to the 
western blots. However, the immunofluorescence data are in agreement with the time 
response experiments (Figure 12). Therefore, EGFR and PHPT1 were ectopically co-
expressed in MCF7 cells and stimulated with EGF (100 ng/mL) for different time 
points. The plotted relative phosphorylation level revealed a decreased phosphorylation 
for the signalling Tyr1068 and a slight increased phosphorylation for the autocatalysis 
site Tyr845 at early time point (5min) (Figure 12). 
 
Figure 12: Temporal regulation of EGFR phosphorylation by PHPT1. EGFR phosphosphorylation of 
the signalling site Tyr1068 (A) and the autocatalysis site Tyr845 (B). Transiently transfected MCF7 cells 
with wt_EGFR_mCitrine and wt_PHPT1_mCitrine were stimulated for different time points with EGF 
(100 ng/mL) and total lysates were analysed via immunoblotting (upper panels). Relative phosphorylation 
level (pY over EGFR) was plotted for the indicated time points (lower panel). 
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EGF in absence and presence of PHPT1 and stained against the specific 
phosphorylation sites in immunofluorescence experiments (Figure 13). 
 
Figure 13: Effect of PHPT1 on EGFR phosphorylation after ligand stimulation with low and high 
doses of EGF. Wt_EGFR_mCitrine and wt_PHPT1_mCherry were ectopically expressed in MCF7. The 
cells were stimulated with different doses of EGF (6 and 50 ng/mL) and stained for the specific phospho 
sites pTyr1068 (A) and pTyr845 (B). Representative fluorescence images for the indicated conditions 
(upper panels). The averaged relative phosphorylation level was plotted for the spatial segments (mean ± 
SEM) (middle panels), while the phosphorylation level of receptor, located at the plasma membrane, was 
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plotted for each single cell (lower panels) (Tyr1068: 6, 50 ng/mL EGF: wt ctrl n=46, 64; wt+PHPT1 
n=29, 49) (Tyr845: 6, 50 ng/mL EGF: wt ctrl n=38, 34; wt+PHPT1 n=31, 31) (mean ± STDEV). 
Furthermore, the obtained averaged phosphorylation levels of EGFR at the plasma 
membrane as well as in the perinuclear area were plotted for the indicated EGF doses 
(Figure 14). 
 
Figure 14: Regulation of EGFR phosphorylation at the plasma and nuclear membrane by PHPT1 
in a dose dependent manner. The relative phosphorylation level was averaged for the specific spatial 
segments including the plasma membrane (left panel) and the nuclear membrane (right panel) for the 
signalling site Tyr1068 (A) and the autocatalysis site Tyr845 (B). The averaged values were plotted 
against ligand concentration (mean ± SEM). 
Regarding to the signalling site Tyr1068, EGFR phosphorylation at the plasma 
membrane and in the perinuclear area was amplified in absence of ligand and low doses, 
whereas PHPT1 led to phosphorylation suppression at high EGF concentration (50-
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equal effect. However, PHPT1 further increased the receptor phosphorylation even at 
saturating amounts of ligand at the plasma and nuclear membrane (Figure 14B). 
4.2  The role of His648 in JM for EGFR activation 
In analogy to the potassium channel KCa3.1, the His648 residue located in the JM of 
EGFR, might act as a possible phosphorylation site. In the case of the ion channel, this 
phosphorylated residue is required for binding active calcium-CaM complex and further 
activation. In recent studies, it has been demonstrated that ligand-induced EGFR 
activation shows similar characteristics with the ion channel KCa3.1 activation, such as 
the CaM binding. This raised the question whether EGFR activation is regulated in a 
related mechanism. In order to answer this question, the importance of the His648 
residue for receptor activation and the role of PHPT1 were investigated by analysing the 
phosphorylation of the JM (H648A) EGFR mutant in absence and presence of PHPT1. 
Therefore, the single His648 residue was mutated to an Ala, which is lacking the 
imidazole ring.  
4.2.1   Spontaneous activation of H648A EGFR in presence of PHPT1 
To investigate the role of the His648 residue on spontaneous EGFR activation, the 
EGFR mutant (H648A) was transfected with increasing amounts of cDNA to artificially 
induce receptor activation in absence of ligand and at high receptor expression level 
(Figure 15). 
 
Figure 15: Phosphorylation of spontaneous activated JM (H648A) EGFR mutant. MCF7 cells were 
transiently transfected with increasing amounts of wt or H648A_EGFR_mCitrine cDNA (0.5, 1.5 and 
3.0 µg). The total lysates of the unstimulated cells were analysed via immunoblotting experiments (left 
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panels) and the relative phosphorylation level (pY over EGFR) of the signalling site Tyr1068 was plotted 
for the determined conditions (right panel). The blots are n=2 (mean ± SEM). 
Densitometric analysis of the western blots revealed that the H648A mutation does not 
affect the spontaneous activation according to the phosphorylation of the signalling site 
Tyr1068. Immunostainings were performed to validate the role of the His648 residue in 
spontaneous receptor activation, as well as if PHPT1 acts on this specific site (Figure 
16). 
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Figure 16: Regulation of spontaneous EGFR activation by PHPT1 and H648A mutation. EGFR 
phosphorylation without EGF treatment of transiently transfected and fixed MCF7 cells for the signalling 
site Tyr1068 (A) and the autocatalysis site Tyr845 (B). Representative fluorescence images for 
H648A_EGFR_mCitrine in absence and presence of wt_PHPT1_mCherry (upper panels). Averaged 
phosphorylation level of segmented single cells plotted against segments (lower, left panel) (Tyr1068: 
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HA n=44, HA+PHPT1 n=26) (Tyr845: HA n=56, HA+PHPT1 n=47) (mean ± SEM). Relative 
phosphorylation level of receptor, located on the plasma membrane (PM), for single cells (lower, right 
panel) (mean ± STDEV). 
As shown in the previous results, the H648A EGFR mutant had no significant effect on 
receptor phosphorylation, regarding to the signalling site Tyr1068 (Figure 16A). In 
contrast to this, the data demonstrated that autocatalysis of spontaneous activated 
receptor (pTyr845), located at the plasma membrane, was increased (Figure 16B). This 
effect was extended in the perinuclear area. PHPT1 amplified the relative wt EGFR 
phosphorylation level of the signalling site Tyr1068 as well as of the H648A EGFR 
mutant. However, the H648A receptor mutant revealed only a slight increase in 
presence of PHPT1, implying the idea that PHPT1 does not only act on the specific 
His648 residue. Whereas the autocatalysis (pTyr845) of H648A EGFR alone and in 
presence of PHPT1 showed the same slight increase raising evidence that PHPT1 
requires an intact His648 residue and may act on this site. 
4.2.2   Ligand dependent activation of H648A EGFR in presence of 
PHPT1 
In addition to the spontaneous activation of EGFR, the well-studied ligand induced 
receptor activation was investigated. Therefore, MCF7 cells ectopically expressing wt 
or H648A EGFR, were stimulated with EGF (100 ng/mL, t=20min) (Figure 17A). After 
ligand stimulation, the H648A mutation increased general EGFR phosphorylation 
(pY72). Next, immunoblotting experiments were performed by staining for the specific 
phospho-sites in order to investigate the amplification effect (Figure 17B). Moreover, 
the cells were stimulated with different doses of EGF to prove the influence of 
phosphorylation in a dose dependent manner.  
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Figure 17: Effect of H648A mutation on ligand dependent EGFR phosphorylation. MCF7 cells were 
transiently transfected with wt or H648A_EGFR_mCitrine. The cells were stimulated with EGF 
(100 ng/mL, t=20min) and stained for general Tyr phosphorylation (pY72) (left panels) (A). The relative 
phosphorylation level (pY over EGFR) of total lysates was quantified for the determined conditions (right 
panel). Transfected MCF7 cells were stimulated with various EGF doses (20min) and stained for the 
specific phospho sites pTyr1068, pTyr845 and pTyr1045 (upper panels) (B). The relative phosphorylation 
level was peak normalized and plotted as a function of the logarithmic EGF concetration for each 
phospho site (lower panel). All blots are n=3 (mean ± SEM). 
Although the phospho-sites Tyr1068 and Tyr845, which are directly connected to EGFR 
activation, showed no effect, the site involved in the amplified phosphorylation has been 
identified. As observed in the experiments, the trafficking phospho-site Tyr1045, which 
recruits c-Cbl after phosphorylation and therefore induces lysosomal receptor 
degradation, was responsible for the effect. Therefore, the sigmoid phosphorylation 
curve was shifted to the left at high EGF doses. Due to the rapid EGFR internalization 
rate, a large section of the receptor molecules was internalized via endocytosis and 
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degraded after 20 min post EGF stimulation. To avoid this degradation effect, EGFR 
phosphorylation was monitored at early stimulation time point (5min). According to 
this, transfected MCF7 cells were stimulated with different doses of EGF for 5min and 
the total lysates were analysed via immunoblotting experiments (Figure 18). 
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Figure 18: Regulation of EGFR phosphorylation in response to EGF by H648A mutation and 
PHPT1. EGFR phosphorylation in an EGF dose dependent manner for the signalling site Tyr1068 (A) 
and the autocatalysis site Tyr845 (B). After EGF stimulation (5min) total lysates were probed (upper 
panels) and the phosphorylation level (pY over Tubulin) of wt and H648A_EGFR_mCitrine in absence 
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and presence of PHPT1 was base line and peak normalized and plotted against the EGF concentration 
(logarithmic) (lower panel). All blots are n=3-5 (mean ± SEM). 
The plotted curves revealed an impaired auto-phosphorylation of the JM (H648A) 
EGFR mutant for the signalling site Tyr1068 in absence and presence of PHPT1 (Figure 
18A) as well as for the autocatalysis site Tyr845 (Figure 18B). Both the H648A mutant 
in absence and presence of PHPT1 demonstrated an equal curve shift distinguishable 
from the phosphorylation of wt EGFR in presence of PHPT1. These findings indicated 
that PHPT1 required an intact His648 residue to influence ligand dependent EGFR 
activation. Moreover, the H648A mutant, mimicking the continuously dephosphorylated 
state, revealed an impaired phosphorylation, which is in agreement with the 
phosphorylation of wt EGFR in presence of PHPT1. In order to validate this inhibiting 
effect, single cell immunofluorescence experiments were performed (Figure 19). 
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Figure 19: Regulation of ligand dependent EGFR phosphorylation by H648A mutation and 
PHPT1. MCF7 cells were transiently transfected, fixed and stained for the specific phospho sites 
pTyr1068 (A) and pTyr845 (B). Representative fluorescence images of phosphorylated EGFR after EGF 
treatment (100 ng/mL, t=5min) (upper panels). Single cells were spatially segmented and the averaged 
phosphorylation level (pY over EGFR) plotted for the calculated segments (lower, left panel) (Tyr1068: 
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HA n=42, HA+PHPT1 n=39) (Tyr845: HA n=52, HA+PHPT1 n=42) (mean ± SEM). Relative 
phosphorylation level of EGFR in the plasma membrane segment for single cells (lower, right panel) 
(mean ± STDEV). 
Indeed, the single cell immunofluorescence experiments showed that the H648A 
mutation in absence and presence of PHPT1 reduced the phosphorylation level of the 
signalling phospho-site Tyr1068 after EGF treatment (100 ng/mL, t=5min) mainly on 
the plasma membrane, consistent with the previous western blot results (Figure 19A). 
However, the ligand-induced autocatalysis of EGFR (pTyr845) was increased by 
PHPT1 and H648A mutation independent of the spatial distribution in the cell (Figure 
19B). The results between immunoblotting and immunofluorescence experiments might 
vary, due to the more precise method based on single cell analysis compared to the cell 
population-based immunoblotting experiments taking all cells in account from low to 
high expression level. Therefore, additional immunofluorescence experiments were 
performed in order to verify the effect of the H648A mutation on EGFR activation in a 
dose dependent manner (Figure 20). 
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Figure 20: Regulation of EGFR phosphorylation in response to EGF by H648A mutation and 
PHPT1. Ligand induced EGFR phosphorylation of the signalling site Tyr1068 (A) and the autocatalysis 
site Tyr845 (B) at low and high EGF dose (6 and 50 ng/mL, 5min). Representative fluorescence images 
of phosphorylated EGFR for the indicated conditions (upper panels). The spatially binned realtive 
phosphorylation level was plotted for each segment (6, 50 ng/mL EGF: Tyr1068: HA n=40, 52, 
HA+PHPT1 n=44, 47) (6, 50 ng/mL EGF: Tyr845: HA n=60, 51, HA+PHPT1 n=47, 54) (mean ± SEM) 
(lower panels). 
Additionally, the relative phosphorylation levels of single cells were plotted for the 
determined conditions (Figure 21). In order to validate the regulation of EGFR 
phosphorylation in space and in response to ligand, the binned phosphorylation level 
was displayed as a function of EGF concentration for the plasma and nuclear membrane 
segment (Figure 22). 
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Figure 21: Single cell phosphorylation level of EGFR affected by PHPT1 and H648A mutation. 
Relative phosphorylation level of EGFR located at the plasma membrane of the signalling phospho site 
Tyr1068 (A) and the autocatalysis site Tyr845 (B)  at low (6 ng/mL) (left panels) and high (50 ng/mL) 
(right panels) EGF dose (mean ± STDEV). 
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Figure 22: Effect of H648A mutation and PHT1 on EGFR phosphorylation at the plasma and 
nuclear membrane in a EGF-dose dependent manner. The relative phosphorylation level of the 
plasma membrane (left panels) and the nuclear membrane segment (right panels) was averaged for the 
different EGF doses and plotted for the specific phosphorylation sites Tyr1068 (A) and Tyr845 (B) 
(mean ± SEM). 
The plots illustrated that PHPT1 increased the ligand-induced auto-phosphorylation of 
Tyr1068 at low EGF concentration (6 ng/mL), at which the receptor mainly becomes 
activated via spontaneous activation (Figure 22A). Therefore, these results are in 
agreement with the increased phosphorylation level of spontaneous activated receptor in 
absence of ligand (Figure 16). In presence of the H648A mutation PHPT1 showed only 
a modest increase; raising the possibility that the His648 residue plays a crucial role to 
regulate the spontaneous EGFR activation by PHPT1 and that PHPT1 might act on this 
position. Moreover, the phosphorylation at saturating dose (100 ng/mL) was reduced by 
both conditions, the H648A mutation and PHPT1 overexpression. This regulation was 
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observed at the plasma membrane (Figure 22A, left panels) as well as in the perinuclear 
area (Figure 22A, right panels). A markedly amplification of phosphorylation was found 
for the autocatalysis site Tyr845 at low and high doses of EGF for both the plasma 
membrane (Figure 22B, left panel) and the perinuclear segment located receptor (Figure 
22B, right panel). However, a combination of both conditions, H648A_EGFR in 
presence of PHPT1, showed an additive effect. 
In order to perform control experiments, a catalytic incompetent PHPT1 (H53A) mutant 
was generated and ectopically co-expressed with wt EGFR (Figure 23)103. The EGFR 
phosphorylation was detected via immunofluorescence experiments. Therefore, the 
spontaneous and ligand induced EGFR activation was affected directly by PHPT1 and 
depends on its catalytic activity (Figure 23). Moreover, except for the autocatalysis of 
ligand induced EGFR activation, the H53A PHPT1 mutant showed the opposite effect 
indicative for a trapped complex, which hampered the general regulation of EGFR 
phosphorylation. These findings supported the idea that PHPT1 affects spontaneous and 
ligand induced EGFR activation in a direct mechanism. 
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Figure 23: EGFR phosphorylation in presence of the catalytic incompetent PHPT1 mutant (H53A) 
in absence and presence of ligand. The relative phosphorylation level of EGFR located at the plasma 
membrane was plotted for single cells (left panels) (mean ± STDEV) as well as the spatially binned and 
averaged values from the plasma to the nuclear membrane (right panels) (mean ± SEM) (0, 100 ng/mL 
EGF: Tyr845: wt n=25, 22; wt+H53A PHPT1 n= 23, 16) (0, 100 ng/mL EGF: Tyr1068: wt n= 26, 31; 
wt+H53A PHPT1 n= 27, 22).  
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4.2.3   EGFR activation in presence of the phosphohistidine kinases 
NME1/2  
The identified phosphatase/kinase system of histidine phosphorylation in vertebrates 
consists of PHPT1, acting as a specific phosphohistidine phosphatase, and the kinases, 
NME1 and NME2, which phosphorylate the targets of PHPT1. In the case that PHPT1 
regulates EGFR activation by dephosphorylating phosphohistidine in a direct or indirect 
manner, the kinases NME1 and NME2 might counteract. To validate the effect of 
NME1 and NME2 on EGFR activation, immunofluorescence experiments were 
performed (Figure 24). 
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Figure 24: Regulation of EGFR phosphorylation by NME1 and NME2. The relative phosphorylation 
level (pY over EGFR) of wt_EGFR_mCit in presence and absence of each kinase (N- or C-terminal 
mCherry) was plotted for spatial segmented single cells for the plasma membrane segment (left panels) 
(mean ± STDEV) and binned for the different segments to show the spatial distribution from the plasma 
membrane to the perinuclear area in the cell (right panels) (mean ± SEM). The phosphorylation of the 
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autocatalysis site Tyr845 (A,B) and the signalling site Tyr1068 (C,D) was detected (0, 100 ng/mL EGF: 
Tyr845: wt n=17, 12; NME1 n= 8, 12; NME2 n= 9, 9) (0, 100 ng/mL EGF: Tyr1068: wt n= 11, 20; 
NME1 n= 14, 26; NME2 n= 25, 22). 
The regulation of spontaneous and ligand induced EGFR activation by different tagged 
kinases (N- or C-terminal) were tested, while only the tagged kinases, affecting EGFR 
activation, were shown here. In agreement with the amplified phosphorylation of the 
autocatalysis site Tyr845 in presence of PHPT1, the phosphorylation was reduced by 
NME1 and NME2 in both cases, the spontaneous and the ligand induced (100 ng/mL, 
5min) EGFR activation (Figure 24A, B). The same consistency was observed for the 
phosphorylation of the signalling site Tyr1068 after EGF dependent receptor activation 
(Figure 24D). The kinase NME1 enhanced EGFR auto-phosphorylation, whereas 
NME2 showed a significant increase only in the cytosolic and perinuclear area. 
However, NME1 and NME2 increased EGFR signalling of spontaneous activated 
receptor such as PHPT1 (Figure 24C). Furthermore, the tagged versions of NME1 and 
NME2, showing an effect for ligand dependent activation, does not influence the 
spontaneous activation. This observation supports the idea that there are two distinct 
regulation mechanisms of EGFR activation in absence and presence of ligand. 
4.3  Effect of PHPT1 and His648 mutation on receptor internalization 
EGFR internalization terminates receptor enrichment on the plasma membrane, thus 
preventing receptor hyperactivation. Spontaneous activated EGFR is internalized and 
recycled back to the plasma membrane via recycling endosomes, whereas ligand-
induced activation leads to internalized receptor, which is degraded via the lysosomal 
pathway. Previous studies showed that the kinases NME1 and NME2 facilitate the 
dynamin-dependent endocytosis104,105. To confirm the effect of PHPT1 and the JM 
(H648A) mutation on receptor internalization, an on-cell western assay based on 
immunofluorescence experiments, and western blot analyses were performed (Figure 
25). 
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Figure 25: PHPT1 and H648A mutation reduces EGFR internalization rate. MCF7 cells were 
transfected with EGFR in absence and presence of PHPT1 in 96 well plates and stimulated with EGF 
(100 ng/mL) for different time points. The fixed, but unpermeabilized cells were stained with EGFR 
antibody (epitope: extracellular part) (A). A representative fluorescence image (upper, left panel) and the 
percentage of receptor sitting on the plasma membrane after EGF stimulation (5min) (upper, right panel) 
and as a function of time (lower panel). The assay was performed as n=2 (mean ± SEM). The normalized 
EGFR expression level (EGFR/Tubulin) was quantified for wt EGFR in absence and presence of PHPT1 
as well as for the H648A EGFR mutant in immunoblotting experiments (B). All blots are n=2 (mean ± 
SEM). 
The data showed that PHPT1 increased the amount of plasma membrane located 
receptor after EGF stimulation (100 ng/mL). Additionally, the JM (H648A) mutation 
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revealed an equal effect at early time point (5min), indicative for a reduced 
internalization rate (Figure 25A). Furthermore, the JM (H648A) mutant increased the 
internalization at late time point (t >15min), which was consistent with a higher 
degradation rate of mutated receptor after EGF stimulation (100 ng/mL, 20min) and an 
increased phosphorylation level of the trafficking phospho-site Tyr1045 in previous 
western blots (Figure 17). To validate this effect, the EGFR expression level of wt and 
H648A EGFR of unstimulated and stimulated (100 ng/mL, 5min) cells was determined 
via western blot analysis (Figure 25B). In agreement with the internalization assay, the 
amount of receptor in unstimulated and stimulated cells was enhanced for wt EGFR in 
presence of PHPT1 and for H648A EGFR, suggesting that receptor internalization is 
reduced by PHPT1 and JM (H648A) mutation. 
4.4  Detection of phosphohistidine in immunoblotting experiments 
To identify the histidine phosphorylation as a new posttranslational modification of 
EGFR, immunoblotting experiments were performed using monoclonal antibodies 
against both isoforms, 1-pHis and 3-pHis106. Although the specific isoforms of in vitro 
auto-phosphorylated enzymes, NME1 and PGAM1 (Figure 26)107,108, have been 
detected in this study, EGFR His phosphorylation could not be identified for 
overexpressed as well as for endogenous receptor in presence of high kinase expression 
level, NME1 and NME2. Due to the unstable phosphoramidate bond and the lack of 
phosphohistidine phosphatase inhibitors, the detection of this modification is 
demanding108. 
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Figure 26: Detection of the phosphohistidine isoforms 1-pHis and 3-pHis. Histidine phosphorylation 
of purified and auto-phosphorylated enzymes. NME1 was incubated in absence (-/-) and presence (-/+) of 
adenosine triphosphate (ATP) (1 mM) at RT for 10min (A) and PGAM1 with 2,3-diphosphoglycerate 
(2,3-DPG) (1 mM) at 30°C for 10min (B). The dephosphorylation of the temperature-sensitive 
phosphohistidine was induced at 95°C for 10min (+/+).    
4.5  Protein interaction between EGFR and PHPT1 
In order to clarify whether the regulation of EGFR activation by PHPT1 undergoes an 
indirect or direct mechanism, co-immunoprecipitation experiments were performed. 
After the optimization procedure, the substrate-trapping mutant of the phosphatase 
(H53A PHPT1) was not eluted in presence of EGFR as well as in the opposite case 
(data not shown). Due to the method, excluding transient interactions, the binding 
between EGFR and PHPT1 may proceed in a short-lived interaction. Therefore, the co-
immunoprecipitation might not be the optimal tool. To further elucidate the protein 
interaction, the more sensitive microscopy method fluorescence lifetime imaging-
fluorescence resonance energy transfer (FLIM-FRET) was performed (Figure 27). 
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Figure 27: Analysis of protein interaction between EGFR and PHPT1 via FLIM-FRET. MCF7 cells 
were transfected with wt_EGFR_mCitrine (donor) and H53A_PHPT1_mCherry (acceptor) (N-terminal 
mCherry (N), C-terminal mCherry (C)) in different ratios (D:A) and stimulated with EGF (100 ng/mL) 
for different time points. The living cells were analysed via FLIM-FRET. Representative fluorescence 
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images and the calculated lifetime (t in ns) (upper panel). The averaged lifetime was plotted for the 
indicated conditions (lower panel). The measurements were performed as n=3-6 (mean ± STDEV). 
The FLIM-FRET experiments, based on an energy transfer between two fluorophores, 
revealed a slight FRET shift between 70 and 80 ps (1:1, (N) and (C)), indicative for a 
transient protein-protein interaction between EGFR and PHPT1.  
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   Discussion 
An increased EGFR activation and amplified signalling is linked to various types of 
cancer28. Therefore, the identification of key players regulating receptor activation plays 
a crucial role. Recent studies have shown that receptor phosphorylation of Tyr as well 
as Ser and Thr residues affect EGFR function in its activity, its endocytosis and further 
signalling38,109. Although these studies provide important insights into EGFR regulation, 
the role of His phosphorylation remains unknown. It has been demonstrated that His 
phosphorylation affects ion channel and G-protein signalling, whereas the receptor 
tyrosine kinase signalling has been overlooked until now91,92,110. To address this issue, 
we investigated the effect of the mammalian phosphohistidine phosphatase and kinase 
cycle, consisting of PHPT1, NME1 and NME2, on EGFR activation. Moreover, we 
elucidated the role of the specific His648 residue, which is located in the polybasic JM 
directly next to the plasma membrane and may act as a possible regulatory 
phosphorylation site. We monitored the EGFR activity by detecting specific receptor 
phosphorylation sites, the signalling site Tyr1068 and the regulatory autocatalysis site 
Tyr845. For the first time, we show the regulation of EGFR activation by PHPT1 and 
the kinases NME1, NME2. The data reveal that the regulation of ligand-induced and 
spontaneous receptor activation might occur in two distinct mechanisms.  
5.1  PHPT1 and JM (H648A) mutation affect spontaneous EGFR 
activation 
In absence of ligand and at high expression level, EGFR undergoes spontaneous 
activation, which requires no stimulus and plays a crucial role in cancerogenesis98,111. 
To investigate the effect of PHPT1 and the JM (H648A) mutation on spontaneous 
EGFR activation, immunoblotting and immunofluorescence experiments of MCF7 
cells, ectopically co-expressing EGFR and PHPT1, were performed. The obtained 
results show that PHPT1 amplifies the signalling (pTyr1068) as well as the 
autocatalysis (pTyr845) of spontaneous activated wt EGFR (Figure 8 and Figure 9). In a 
model in which EGFR activation is regulated in a related mechanism as the ion channel 
KCa3.1, the His648 residue gets phosphorylated, while PHPT1 catalyses the 
dephosphorylation. Subsequently, the embedded state would be favoured due to a 
hampered release of the intracellular part. EGFR may be trapped in the plasma 
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membrane causing an increased density of receptor molecules. Since the spontaneous 
EGFR activation depends on the amount of plasma membrane bound receptor, an 
increased density enhances the possibility of two monomers coming in contact via 
thermal fluctuation and therefore enhances the spontaneous activation.  
In contrast to PHPT1, the JM (H648A) mutation of EGFR shows no effect on EGFR 
signalling (pTyr1068) in absence of ligand (Figure 15 and Figure 16), whereas the 
autocatalysis (pTyr845) is slightly increased (Figure 16). There is probably a safeguard 
mechanism, preventing a propagation of this amplifying effect to downstream 
signalling.  
To ascertain if the specific His648 residue serves as a substrate site for PHPT1, the 
effect of the phosphatase on the H648A EGFR mutant was analysed. The 
immunofluorescence experiments reveal the same autocatalysis level (pTyr845) for the 
H648A EGFR mutant alone as well as in presence of PHPT1, while the signalling is 
slightly increased (Figure 16). In both cases, autocatalysis and signalling, the relative 
phosphorylation level is distinguishable from wt EGFR phosphorylation in presence of 
PHPT1. This suggests the idea that PHPT1 requires an intact His648 residue in the JM 
of EGFR to affect spontaneous receptor activation. It also indicates that PHPT1 may act 
directly on this residue. For EGFR signalling (pTyr1068) the H648A mutation hampers 
the amplification by PHPT1, but not completely. Therefore, it is tempting to speculate 
that PHPT1 acts on further His residues or that the enzyme increases EGFR signalling 
of spontaneous activated receptor not only via His dephosphorylation. The phosphatase 
may serve additionally as an allosteric regulator or as a binding partner, stabilizing a 
protein complex crucial for spontaneous receptor signalling. The amplified signalling 
(pTyr1068) as well as the autocatalysis (pTyr845) depend on the catalytic activity of 
PHPT1 (Figure 23). The catalytic inactive PHPT1 mutant (H53A) does not only act as a 
catalytically incompetent mutant, but also as a substrate trapping mutant79,20. As a 
substrate trapping mutant, PHPT1 H53A would bind EGFR and traps it into a complex 
caused by its incapacity to catalyse the dephosphorylation of the receptor. Therefore, wt 
EGFR activation and further phosphorylation would be impaired, which could be 
observed in the previous experiments. 
The regulation of EGFR phosphorylation in the cell shows a high complexity. 
Therefore, the phosphorylation is not only modulated in a temporal and a ligand dose 
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dependent manner, but also by endocytosis in a spatial manner. Using the single cell 
segmented immunofluorescence data, the regulation of EGFR phosphorylation has been 
quantified in space, showing an altered spatial regulation between the signalling 
(pTyr1068) and the autocatalysis (Tyr845) phosphorylation (Figure 16). The 
phosphorylation of the signalling site (Tyr1068) has been amplified all over the cell, 
while the autocatalysis site (Tyr845) shows the strongest amplification in the 
perinuclear area. The autocatalysis site is located in the activation loop, which may lose 
its accessibility to become phosphorylated in the embedded state by facing the plasma 
membrane, while the signalling site is located in the accessible flexible C-terminus. 
During endocytosis, the stabilization of the embedded receptor state, containing a non-
accessible Tyr845 site, might be decreased, which would enhance the possibility of 
Tyr845 phosphorylation of EGFR in the cytosol. 
5.2  Regulation of ligand induced EGFR activation by PHPT1 and JM 
(H648A) mutation 
In addition to the spontaneous activation, EGFR gets also activated in presence of 
ligand. Therefore, ligand binding generates an asymmetric dimer conformation, which 
activates the receptor tyrosine kinase and induces trans-phosphorylation. To uncover the 
effect of PHPT1 on the ligand induced EGFR activation, EGF dose response 
experiments were performed (Figure 10). The results reveal a significant right shift of 
the signalling phosphorylation (pTyr1068) in presence of PHPT1, indicative for a 
changed threshold, which means that EGFR requires an increased amount of EGF to get 
activated. Only a slight right shift has been observed for the phosphorylation of the 
autocatalysis site (pTyr845). To further validate this effect, immunofluorescence 
experiments were performed, showing consistently a decrease of phosphorylation for 
EGFR signalling at high EGF concentration (Figure 14). In contrast to the western blots, 
the immunofluorescence experiments show an amplified phosphorylation of the 
autocatalysis site (pTyr845). This might be due to the more precise single cell method, 
whereas the western blot is based on a cell population based assay taking all cells with 
low and high EGFR and PHPT1 expression level into account, which might falsify the 
results of only weak effects.  
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EGFR recycles back to the plasma membrane via the clathrin dependent pathway at low 
EGF doses, whereas high doses induce lysosomal EGFR degradation via the clathrin 
independent pathway112. This change in trafficking may be caused by a shift from the 
monomeric spontaneous activation to the dimeric ligand induced activation and may 
explain the obtained results. At low doses (0-50ng/mL) EGFR signalling (pTyr1068) is 
amplified consistent with the data of spontaneous activated receptor in absence of ligand 
(Figure 9 and Figure 14), while PHPT1 suppresses the phosphorylation increase at high 
doses (>50 ng/mL). Previous studies have reported that CaM facilitates ligand 
dependent activation by releasing the intracellular part of EGFR from the plasma 
membrane, thus enables the dimerization. However, the role of CaM for the 
spontaneous activation of EGFR in absence of ligand has not been defined113. If the 
CaM dependent activation requires the phosphohistidine (pHis648), the 
dephosphorylation by PHPT1 would hamper the dimerization by a continuously 
embedded inactive state causing a decreased phosphorylation at high EGF doses. 
Furthermore, phosphorylation of Thr654 and Thr669, located in the JM region of 
EGFR, shifts the monomer-dimer equilibrium of ligand bound receptor towards the 
monomeric state, while Thr669 phosphorylation inhibits CaM binding and therefore 
further ligand induced EGFR activation114,65. This raises evidence that PHPT1 may 
modulate the monomer-dimer equilibrium of EGFR by affecting CaM binding. 
In general, EGFR phosphorylation is coupled to PTP inhibition by reactive oxygen 
species (ROS), like H2O2. Therefore, ligand-induced EGFR activation produces an 
increased amount of ROS at the plasma membrane via sequential activation of PI3K and 
Rac1, which binds and activates specific NADPH oxidases (NOX) located in the plasma 
membrane115. Since ROS oxidizes the catalytic cysteine residue of PTPs, the inactive 
phosphatases are not able to dephosphorylate EGFR116. This coupling causes a double 
negative feedback, which leads to an increased amount of phosphorylated receptor in 
presence of high EGF doses at the plasma membrane45. In contrast to the PTPs, PHPT1 
gets oxidized at Met95 in presence of H2O2. This residue is located in the substrate 
binding site, but does not impair the functionality of PHPT1117. Therefore, PHPT1 is 
able to affect ligand induced EGFR signalling even at high EGF doses by suppressing 
the switch-like receptor response. In contrast to the signalling (pTyr1068), the 
autocatalysis (pTyr845) is still amplified at high doses of EGF. Recent studies have 
been demonstrated that ROS activates the Src kinase in MCF7 cells.118 Hence, the Src 
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kinase also phosphorylates the autocatalysis site (Tyr845), an increased kinase activity 
may overcome the suppressing effect of PHPT1. This is confirmed by a sustained 
increased EGFR autocatalysis in presence of ligand by the catalytic incompetent PHPT1 
mutant (Figure 23).  
The immunofluorescence experiments show that not only PHPT1 overexpression, but 
also H648A JM mutation reduce the ligand induced EGFR signalling at high EGF doses 
(Figure 22), consistent with recent reports in which mutations in the CaM binding 
domain decreases EGFR phosphorylation in presence of ligand61. Therefore, the H648A 
JM mutation, mimicking a continuously dephosphorylated state located in the CaM 
binding domain of EGFR64, might prevent CaM binding, which requires His 
phosphorylation in the case of the ion channel KCa3.1. If EGFR is regulated in 
analogous to KCa3.1, this would impede the ligand dependent receptor activation and 
lead to a reduced phosphorylation and attenuated signalling, which has been shown in 
the experiments. The H648A JM mutant has the same effect in presence of PHPT1, 
which raises the possibility that PHPT1 acts on the His648 residue. Moreover, the 
catalytically incompetent PHPT1 mutant (H53A) shows the opposite effect of ligand 
induced EGFR phosphorylation at high EGF dose (Figure 23). 
Controversially, the autocatalysis (pTyr845), which is directly connected to the 
signalling, is increased for the JM H648A mutation and in presence of PHPT1. This 
effect is amplified for H648A EGFR in presence of PHPT1. In previous studies, it has 
been demonstrated that PHPT1 inhibits certain targets such as KCa3.1 and ACL, which 
impair the Src kinase activity119,120. An inhibition of these targets would increase Src 
activation which causes an amplified phosphorylation of the autocatalysis site. Since the 
autocatalysis site Tyr845 becomes not only auto-phosphorylated, but also external 
phosphorylated by the Src kinase40, PHPT1 overexpression may lead to an amplified 
Src activity causing an increased phosphorylation of the autocatalysis site Tyr845. This 
may prevent the inhibitory effect of PHPT1 at high EGF doses. 
5.3  Regulation of EGFR activation by phosphohistidine kinases NME1 
and NME2 
The kinases NME1 and NME2 catalyse the phosphorylation of His residues. While 
PHPT1 has been identified as an oncogene, NME1 and NME2 are known as metastasis 
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suppressor genes. In the performed immunofluorescence experiments, the kinases 
showed the opposite effect compared to PHPT1 (Figure 24). Thus, the data reveals a 
decreased autocatalysis of EGFR (pTyr845) of spontaneous and ligand induced 
activated receptor as well as an increase of ligand dependent EGFR signalling 
(pTyr1068) raising evidence that the kinases counteract PHPT1. However, NME1 and 
NME2 enhanced EGFR signalling in absence of ligand equal to PHPT1. Since EGFR 
downstream signalling varies between spontaneous and ligand dependent receptor 
activation46, NME might regulate the downstream signalling of spontaneous activated 
EGFR in a different way, which remains unknown at this state. Therefore, further 
experiments have to be performed. Moreover, the functionality of NME1 and NME2 is 
affected by the localization of the tagged fluorophore. Indeed, different tagged versions 
regulate spontaneous and ligand induced receptor activation, which indicates that both 
activation mechanisms are regulated by NME1 and NME2 in two distinct mechanisms. 
Finally, both kinases may act as metastasis suppressor genes caused by an impaired 
EGFR activity. 
5.4  PHPT1 and JM (H648A) mutation attenuate EGFR internalization 
EGFR activity on the plasma membrane is also regulated by endocytosis, where 
receptor molecules get internalized after activation. Upon stimulus, the receptor 
becomes internalized and degraded through lysosomes, whereas spontaneous activated 
receptors (non-ligand dependent) are recycled back to the plasma membrane through the 
recycling endosomes47,46. Moreover, previous studies have shown that NME1 and 
NME2 facilitate dynamin-mediated endocytosis by interacting with and providing GTP 
to dynamins105,121. Since active dynamin is required for EGFR endocytosis, an 
internalization assay has been performed to validate the effect of PHPT1 and the H648A 
JM mutation of EGFR on receptor internalization rate (Figure 25A). The assay reveals 
an increased amount of EGFR on the plasma membrane after EGF stimulation in 
presence of PHPT1, indicative for a decreased internalization rate. The same effect has 
been observed for the JM H648A EGFR mutant at early time point (5min) and could be 
confirmed via immunoblotting experiments (Figure 25B). The reduced internalization 
rate is consistent with the previous results, where the spontaneous activation, inducing 
recycling, has been amplified, while the ligand dependent activation, inducing receptor 
degradation, is reduced. Additionally, an increased density of receptor molecules on the 
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plasma membrane amplifies the spontaneous EGFR activation by increasing the 
possibility of receptor molecules encounter each other and forming a short-lived dimer 
for activation. It is possible that PHPT1 does not only regulate EGFR activation in a 
direct manner; it may also play a crucial role in an indirect mechanism by affecting the 
endocytosis rate. While the effect on endocytosis has been discussed as a crucial factor 
involved in the tumour suppressor activity of NMEs, with respect to PHPT1 it may 
cause its oncogenic potential104. 
5.5  Phosphohistidine detection with immunoblotting experiments 
The phosphorylation of His occurs on two possible positions, forming two isoforms 1-
pHis and 3-pHis containing an unstable phosphoramidate. This high-energy bond is less 
stable against hydrolysis compared to the general phosphohydroxyamino acids such as 
pTyr, pSer or pThr. Due to its acid and temperature sensitivity, the detection turns out to 
be demanding. During this work the His phosphorylation of in vitro auto-
phosphorylated enzymes (NME1 and PGAM1) was detected, while EGFR 
phosphohistidine remained undetected (Figure 26). Reasons for this may be the 
dephosphorylation during lysis procedure caused by the lack of phosphohistidine 
phosphatase inhibitors. Therefore, previous studies have shown that unspecific 
phosphohistidine phosphatases such as PP1, PP2A and PP2C exist, which might be able 
to dephosphorylate EGFR. Even if cell lines with low PHPT1 endogenous level have 
been chosen, these phosphatases may falsify the results. The detection of total lysates 
containing ectopically overexpressed EGFR as well as concentrated receptor samples 
after immunoprecipitation of endogenous receptor was unsuccessful. EGFR may form a 
transient phosphohistidine intermediate, which transfers its phosphate directly after 
phosphorylation. This would also circumvent the detection of phosphorylated histidine. 
5.6  Protein interaction between EGFR and PHPT1 
 In order to identify the direct interaction between PHPT1 and EGFR, co-
immunoprecipitation experiments were performed. Therefore, a substrate trapping 
PHPT1 mutant (H53A) was generated and ectopically co-expressed with EGFR in 
MCF7 cells. Since the method includes only strong protein-protein interactions and the 
binding may proceed in a transient short-lived interaction, co-immunoprecipitation is 
probably not the optimal tool and could not be used to detect a direct interaction 
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between EGFR and PHPT1. Therefore, a more sensitive and precise fluorescence 
microscopy method, FLIM-FRET, was performed (Figure 27). FRET is based on a non-
radiative energy transfer between a donor and an acceptor molecule. This transfer 
induces a reduced life time (t) of the donor fluorophore, which is detected by FLIM. 
The FRET efficiency depends on a correct dipole-dipole coupling based on the distance 
and the orientation between the dipole moments of the donor and acceptor molecule122. 
In the performed FLIM-FRET experiments of wt EGFR, C-terminally tagged with 
mCitrine, and H53A PHPT1, N-terminal tagged with mCherry, a shift in life time of 70 
to 80 ps was observed. Although this change is low, it raises evidence that PHPT1 
probably interact with EGFR. Increased distances between the two fluorophores may 
cause a decreased FRET efficiency. PHPT1 might bind EGFR through a secondary 
binding partner. By forming a sterically hindered protein complex, the dipole-dipole 
coupling might be impaired. If the resulting protein complex is too labile, the detection 
of protein interaction between EGFR and PHPT1 would be also unsuccessful via co-
immunoprecipitation. Additionally, the fluorescence protein mCherry, which is linked 
to PHPT1, has a molecular weight of 27 kDa, while the small phosphatase PHPT1 has 
only a molecular weight of 14 kDa. According to this, the size of the recombinant 
protein used for the studies is three-fold higher as the phosphatase. This increase in size 
might also hamper PHPT1 binding, due to sterically hindrance, in FLIM-FRET as well 
as co-immunoprecipitation experiments. 
5.7  A proposed model of EGFR activation regulated by 
phosphohistidine phosphatase/kinase cycle 
Despite the open questions concerning the His phosphorylation of EGFR and the direct 
interaction between EGFR and PHPT1, this study has identified the first 
phosphohistidine phosphatase regulated EGFR activation mechanism. This pioneering 
work goes one step further and shows that EGFR autocatalysis and signalling of 
spontaneous as well as ligand induced receptor activation are regulated by the 
phosphohistidine phosphatase/kinase cycle. Accordingly, not only GPCR and calcium 
signalling are regulated by His phosphorylation, but also RTK signalling. 
Based on the assumption that PHPT1 regulates EGFR in a direct manner, a mechanistic 
model is proposed (Figure 28).  
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Figure 28: Model of EGFR activation regulated by phosphohistidine phosphatase/kinase cycle. 
Vesicular trafficking (thick arrows) of EGFR from plasma membrane via early endosomes (EE). 
Monomers are recycled back to the plasma membrane via recycling endosomes (RE), while formed 
dimers are degraded by lysosomes. Extracellular part is excluded for simplification. Horizontal arrows: 
conversion. Vertical arrows: causality. 
In this model, EGFR becomes His phosphorylated (His648) in its polybasic JM by 
NME1/2, which is required for binding active calcium-CaM complex. The negatively 
charged CaM repeals the embedded intracellular part from the plasma membrane and 
facilitates dimerization by increasing the flexibility of the receptor. This causes an 
increased EGFR signalling of ligand induced receptor activation in presence of 
NME1/2. As opposed to this, PHPT1 dephosphorylates the phosphohistidine (pHis648) 
to hamper the ligand dependent dimerization by favouring the inactive embedded state 
of EGFR, which induces a decreased EGFR signalling (Figure 29A). Subsequently, 
EGFR is trapped in the plasma membrane leading to an increased density of plasma 
membrane bound receptor. Previous studies have shown that spontaneous EGFR 
activation depends on its expression level98. Therefore, an increased amount of receptor 
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on plasma membrane enhances the probability of two molecules coming together and 
forming a short-lived dimer for further receptor activation. As the experiments have 
shown, the receptor internalization is decreased in presence of PHPT1 as well as for the 
JM H648A mutation. The signalling and autocatalysis of spontaneous receptor 
activation might be amplified by modulating the endocytosis of EGFR. While the ligand 
induced EGFR signalling is reduced by PHPT1, the autocatalysis, which is directly 
connected to the signalling, shows an amplification (Figure 29B). This amplified effect 
might be caused by an increased Src kinase activity, which might amplify the 
phosphorylation of the autocatalysis site Tyr845 and therefore suppresses the inhibitory 
effect of PHPT1. 
 
Figure 29: Scheme for EGFR activity regulation by PHPT1. (A) PHPT1 amplifies EGFR signalling 
(pTyr1068) of spontaneous acitvated recepor, while the ligand induced activation is de00creased. (B) 
Autocatalysis of spontanoues activated EGFR (pTyr845) is increased by PHPT1 in a direct mechanism, 
while the ligand induced activation might be amplified through an indirect mechanism. 
While PHPT1 might reduce the ligand dependent activation by suppressing the 
formation of the active asymmetric dimer state via pHis648 dephosphorylation, an 
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impaired EGFR endocytosis process might amplify the spontaneous activation. This 
implies two distinct regulation mechanisms between the ligand independent and 
dependent EGFR activation by PHPT1. 
In addition to EGFR, the other members of the ErbB family (ErbB2, ErbB3 and ErbB4) 
might reveal a related regulation mechanism. Instead of the His residue in EGFR, 
ErbB2 contains a Gln, ErbB3 an arginine (Arg) and ErbB4 a Ser residue. Therefore, the 
Arg and Ser might also become phosphorylated, affecting the activation of ErbB2 and 
ErbB4. 
PHPT1 has been identified as an oncogene. This raises the question if its oncogenic 
potential originates from the amplified spontaneous EGFR activation. Both oncogenes, 
PHPT1 and EGFR, are involved in the tumour invasion and migration in lung cancer 
cell lines29,76,77. Moreover, EGFR is involved in the malignancy of glioblastoma cells, 
which shows a high expression level of PHPT178,123. By connecting these two 
oncogenes, PHPT1 itself might become a potential drug target.  
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   Future Directions 
During this study PHPT1 has been identified as a new key player in regulating EGFR 
activation for the first time. This work shows that EGFR autocatalysis and signalling of 
spontaneous- as well as ligand-induced receptor activation events are regulated by the 
phosphohistidine phosphatase/kinase cycle.  
As mentioned before, only a piece of the puzzle has been discovered. To solve this 
puzzle, further experiments have to be performed in the near future. First of all, the His 
phosphorylation of EGFR has to be detected. Since the staining with monoclonal 
antibodies in immunoblotting experiments was unsuccessful, the next step would be to 
use mass spectrometry to monitor the phosphohistidine at the specific His648 residue106. 
In order to further validate the proposed model, the effect of PHPT1 on the interaction 
between EGFR and CaM has to be elucidated. One possibility to test this hypothesis is 
the FLIM-FRET approach. By measuring FRET between EGFR mCitrine and CaM 
mCherry in presence of PHPT1 and the H648A JM mutation, the hypothesis that 
PHPT1 activity hampers CaM binding and thus impede receptor dimerization and 
further activation can be tested. 
Another piece of the puzzle is formed by the conformational fluctuation of the receptor. 
If EGFR is regulated as described in the model, dephosphorylation catalysed by PHPT1 
would hamper the release of the intracellular part of EGFR generating a less flexible 
receptor, which is stuck to the plasma membrane. Therefore, the increased rigidity can 
be detected by fluorescence anisotropy. This method uses the change of fluorescence 
polarization caused by an altered molecular orientation of the receptor124. 
To finalize the overall picture, the influence on the endocytosis divided into recycling 
and lysosomal degradation has to be validated in detail. There are several techniques to 
visualize EGFR endocytosis. One of these is the imaging in living cells by fluorescence 
microscopy. To validate if the kinases NME1 and NME2 reduce EGFR phosphorylation 
by increasing the internalization rate, a dynamin inhibitor can be used. Additionally, 
fluorescently labelled EGF is used to detect the ligand bound EGFR complex during 
endocytosis. A second approach could be the use of an ubiquitination assay based on the 
detection of ubiquitin bound to immunoprecipitated EGFR by western blotting125. 
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Finally, the obtained results in this study are generated by an artificial system in which 
EGFR and PHPT1 are ectopically overexpressed in MCF7 cells. To further confirm the 
regulation of EGFR activation by PHPT1, the receptor phosphorylation has to be 
validated at endogenous level. Therefore, knock down of protein expression level with 
small interfering ribonucleic acid (siRNA) or the clustered regulatory interspaced short 
palindromic repeats/Cas (CRISPR/Cas) method could be performed.  
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   Supplementary Material 
Table 11: Primer sequences for cloning and quick change PCR. 
Gene Vector Primer Sequence 
PHPT1 pmCherry-C1 Forward CAAGCTTCGATGGCAGTGGCGGACCTC 
PHPT1 pmCherry-C1 Reverse CGCGGTACCTTAGTAGCCGTCGTTAGCCCAGG 
PHPT1 pmCherry-N1 Forward CTCAAGCTTATGGCAGTGGCGGACCTC 
PHPT1 pmCherry-N1 Reverse CGCGGTACCGTGTAGCCGTCGTTAGCCCAGGTGAC
CTCG 
PHPT1_H53A - QC AAGTGGGCTGAGTACGCGGCGGACATCTACGAC 
NME1 pmCherry-C1 Forward ATCTCGAGCTCAAGCTTCGATGGCCAACTGTGAGC
GTAC  
NME1   pmCherry-C1   Reverse   GTACCGTCGACTGCAGAATTTCATTCATAGATCCAG
TTCTGAGCACAG  
NME1   pmCherry-N1   Forward   CGAATTCTGCAGTCGACGGTACATGGCCAACTGTG
AGCGAC 
NME1   pmCherry-N1   Reverse   GGATCCCGGGCCCGCGGTACCGTTTCATAGATCCA
GTTCTGAGCACAGC  
NME2   pmCherry-C1   Forward   GATCTCGAGCTCAAGCTTCGATGGCCAACCTGGAG
CGCAC 
NME2   pmCherry-C1   Reverse   GTACCGTCGACTGCAGAATTTCATTCATAGACCCA
GTCATAGCACAAG  
NME2   pmCherry-N1   Forward   GAATTCTGCAGTCGACGGTACATGGCCAACCTGGA
GCG 
NME2   pmCherry-N1   Reverse   CGGTGGATCCCGGGCCCGCGGTACCGTTTCATAGA
CCCAGTCATGAGCACAAG  
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